<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome - Sharpe, A - 2019 | Cochrane Library</title> <meta content="Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome - Sharpe, A - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013505/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome - Sharpe, A - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013505/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013505" name="dc.identifier" scheme="DOI"/> <meta content="Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome" name="citation_title"/> <meta content="Abigail Sharpe" name="citation_author"/> <meta content="University of Leeds" name="citation_author_institution"/> <meta content="Lara C Morley" name="citation_author"/> <meta content="The General Infirmary of Leeds" name="citation_author_institution"/> <meta content="Thomas Tang" name="citation_author"/> <meta content="Royal Jubilee Maternity Service" name="citation_author_institution"/> <meta content="tommy.tang@belfasttrust.hscni.net" name="citation_author_email"/> <meta content="Robert J Norman" name="citation_author"/> <meta content="Adam H Balen" name="citation_author"/> <meta content="The Leeds Centre for Reproductive Medicine, Seacroft Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD013505" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013505/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013505/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013505/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene [therapeutic use]; Fertility Agents, Female [therapeutic use]; Infertility, Female [therapy]; Metformin [*therapeutic use]; Ovary [surgery]; Ovulation Induction [*methods]; Polycystic Ovary Syndrome [*complications]; Pregnancy Outcome; Pregnancy Rate; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013505&amp;doi=10.1002/14651858.CD013505&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013505\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013505\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","ms","ja","fa","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013505",title:"Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome",firstPublishedDate:"Dec 17, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013505&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013505';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013505/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013505/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013505%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013505/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013505/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013505/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013505/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013505" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013505/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013505" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013505/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013505/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12755 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013505" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0184"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-sec-0170"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013505/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/appendices#CD013505-sec-0189"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/table_n/CD013505StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/table_n/CD013505StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013505/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013505/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013505/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013505/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013505/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013505/information#CD013505-cr-0002">Abigail Sharpe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013505/information#CD013505-cr-0003">Lara C Morley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013505/information#CD013505-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Thomas Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013505/information#CD013505-cr-0005">Robert J Norman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013505/information#CD013505-cr-0006">Adam H Balen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013505/information/en#CD013505-sec-0199">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013505/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013505">https://doi.org/10.1002/14651858.CD013505</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013505-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013505-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013505-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013505-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD013505-abs-0002">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013505-abs-0001" lang="en"> <section id="CD013505-sec-0001"> <h3 class="title" id="CD013505-sec-0001">Background</h3> <p>Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia occurs secondary to insulin resistance and is associated with an increased biochemical risk profile for cardiovascular disease and an increased prevalence of diabetes mellitus. Insulin‐sensitising agents such as metformin may be effective in treating PCOS‐related anovulation. This is an update of <a href="http://Morley 2017" target="_blank">Morley 2017</a> and only includes studies on metformin. </p> </section> <section id="CD013505-sec-0002"> <h3 class="title" id="CD013505-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of metformin in combination with or in comparison to clomiphene citrate (CC), letrozole and laparoscopic ovarian drilling (LOD) in improving reproductive outcomes and associated gastrointestinal side effects for women with PCOS undergoing ovulation induction. </p> </section> <section id="CD013505-sec-0003"> <h3 class="title" id="CD013505-sec-0003">Search methods</h3> <p>We searched the following databases from inception to December 2018: Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL. We searched registers of ongoing trials and reference lists from relevant studies. </p> </section> <section id="CD013505-sec-0004"> <h3 class="title" id="CD013505-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of metformin compared with placebo, no treatment, or in combination with or compared with CC, letrozole and LOD for women with PCOS subfertility. </p> </section> <section id="CD013505-sec-0005"> <h3 class="title" id="CD013505-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for eligibility and bias. Primary outcomes were live birth rate and gastrointestinal adverse effects. Secondary outcomes included other pregnancy outcomes and ovulation. We combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity using the I<sup>2</sup> statistic and reported quality of the evidence for primary outcomes and reproductive outcomes using GRADE methodology. </p> </section> <section id="CD013505-sec-0006"> <h3 class="title" id="CD013505-sec-0006">Main results</h3> <p>We included 41 studies (4552 women). Evidence quality ranged from very low to moderate based on GRADE assessment. Limitations were risk of bias (poor reporting of methodology and incomplete outcome data), imprecision and inconsistency. </p> <p><b>Metformin versus placebo or no treatment</b> </p> <p>The evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51; I<sup>2</sup> = 0%; 4 studies, 435 women; low‐quality evidence). For a live birth rate of 19% following placebo, the live birth rate following metformin would be between 19% and 37%. The metformin group probably experiences more gastrointestinal side effects (OR 4.00, 95% CI 2.63 to 6.09; I<sup>2</sup> = 39%; 7 studies, 713 women; moderate‐quality evidence). With placebo, the risk of gastrointestinal side effects is 10% whereas with metformin this risk is between 22% and 40%. There are probably higher rates of clinical pregnancy (OR 1.98, 95% CI 1.47 to 2.65; I<sup>2</sup> = 30%; 11 studies, 1213 women; moderate‐quality evidence). There may be higher rates of ovulation with metformin (OR 2.64, 95% CI 1.85 to 3.75; I<sup>2</sup> = 61%; 13 studies, 684 women; low‐quality evidence). We are uncertain about the effect on miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35; I<sup>2</sup> = 0%; 4 studies, 748 women; low‐quality evidence). </p> <p><b>Metformin plus CC versus CC alone</b> </p> <p>We are uncertain if metformin plus CC improves live birth rates compared to CC alone (OR 1.27, 95% CI 0.98 to 1.65; I<sup>2</sup> = 28%; 10 studies, 1219 women; low‐quality evidence), but gastrointestinal side effects are probably more common with combined therapy (OR 4.26, 95% CI 2.83 to 6.40; I<sup>2</sup> = 8%; 6 studies, 852 women; moderate quality evidence). The live birth rate with CC alone is 24%, which may change to between 23% to 34% with combined therapy. With CC alone, the risk of gastrointestinal side effects is 9%, which increases to between 21% to 37% with combined therapy. The combined therapy group probably has higher rates of clinical pregnancy (OR 1.62, 95% CI 1.32 to 1.99; I<sup>2</sup> = 31%; 19 studies, 1790 women; moderate‐quality evidence). The combined group may have higher rates of ovulation (OR 1.65, 95% CI 1.35 to 2.03; I<sup>2</sup> = 63%;21 studies, 1568 women; low‐quality evidence). There was no clear evidence of an effect on miscarriage (OR 1.35, 95% CI 0.91 to 2.00; I<sup>2</sup> = 0%; 10 studies, 1206 women; low‐quality evidence). </p> <p><b>Metformin versus CC</b> </p> <p>When all studies were combined, findings for live birth were inconclusive and inconsistent (OR 0.71, 95% CI 0.49 to 1.01; I<sup>2</sup> = 86%; 5 studies, 741 women; very low‐quality evidence). In subgroup analysis by obesity status, obese women had a lower birth rate in the metformin group (OR 0.30, 95% CI 0.17 to 0.52; 2 studies, 500 women), while the non‐obese group showed a possible benefit from metformin, with high heterogeneity (OR 1.71, 95% CI 1.00 to 2.94; I<sup>2</sup> = 78%, 3 studies, 241 women; very low‐quality evidence). However, due to the very low quality of the evidence we cannot draw any conclusions. Among obese women taking metformin there may be lower rates of clinical pregnancy (OR 0.34, 95% CI 0.21 to 0.55; I<sup>2</sup> = 0%; 2 studies, 500 women; low‐quality evidence) and ovulation (OR 0.29, 95% CI 0.20 to 0.43; I<sup>2</sup> = 0%; 2 studies, 500 women; low‐quality evidence) while among non‐obese women, the metformin group may have more pregnancies (OR 1.56, 95% CI 1.06 to 2.29; I<sup>2</sup> = 26%; 6 studies, 530 women; low‐quality evidence) and no clear difference in ovulation rates (OR 0.80, 95% CI 0.52 to 1.25; I<sup>2</sup> = 0%; 5 studies, 352 women; low‐quality evidence). We are uncertain whether there is a difference in miscarriage rates between the groups (overall: OR 0.92, 95% CI 0.51 to 1.66; I<sup>2</sup> = 36%; 6 studies, 781 women; low‐quality evidence) and no studies reported gastrointestinal side effects. </p> </section> <section id="CD013505-sec-0007"> <h3 class="title" id="CD013505-sec-0007">Authors' conclusions</h3> <p>Our updated review suggests that metformin may be beneficial over placebo for live birth however, more women probably experience gastrointestinal side effects. We are uncertain if metformin plus CC improves live birth rates compared to CC alone, but gastrointestinal side effects are probably increased with combined therapy. When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence. Results differed by body mass index (BMI), emphasising the importance of stratifying results by BMI. No studies reported gastrointestinal side effects in this comparison. Due to the low quality of the evidence, we are uncertain of the effect of metformin on miscarriage in all three comparisons. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013505-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013505-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013505-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013505-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013505-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013505-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013505-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD013505-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013505-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013505-abs-0005" lang="en"> <h3>Metformin for ovulation induction in women with a diagnosis of polycystic ovary syndrome and subfertility </h3> <p><b>Review question</b> </p> <p>Researchers reviewed the evidence about the effectiveness and safety of metformin compared with other ovulation induction agents, for inducing ovulation in women with polycystic ovary syndrome (PCOS). Of interest were live birth rate, gastrointestinal side effects and additional reproductive outcomes. </p> <p><b>Background</b> </p> <p>Women with PCOS often have infrequent or no periods because they do not ovulate (release an egg), which can result in infertility. They may also develop problems such as obesity and diabetes. High levels of insulin, a hormone that allows the body to use sugar for energy, may be a cause of PCOS and levels are generally higher in obese women. Metformin helps the body use insulin more effectively and improves ovulation in women with PCOS. However, metformin may cause side effects such as nausea, diarrhoea or constipation (gastrointestinal side effects). </p> <p><b>Study characteristics</b> </p> <p>We searched for studies in women with PCOS that compared metformin alone or with CC, letrozole or LOD, against CC, letrozole, LOD, placebo (sham treatment) or no treatment. This review updates the previous version of the review. We included 41 randomised controlled trials (where women were randomly allocated to a treatment) with 4552 women. 13 studies are new for this update. We combined results from the studies and assessed the quality of the studies to judge how confident we could be in their results. The evidence is current up to December 2018. </p> <p><b>Key results</b> </p> <p><b>Metformin versus placebo/no treatment</b> </p> <p>Metformin may increase the chances of having a live birth compared with no treatment or placebo, however women taking metformin probably experience more gastrointestinal side effects. With placebo, the live birth rate is 19%, and it would be between 19% and 37% with metformin. The risk of gastrointestinal side effects is 10% with placebo, but higher with metformin, between 22% and 40%. Women taking metformin are probably more likely to get pregnant and may be more likely to ovulate. We are uncertain about the effect of metformin compared to placebo or no treatment on miscarriage. </p> <p><b>Metformin plus CC versus CC alone</b> </p> <p>We are uncertain if metformin plus CC improves live birth rate compared to CC alone, but gastrointestinal side effects are probably more common. The live birth rate with CC alone is 24% which may change to between 23% to 34% with metformin and CC combined. With CC alone, the risk of gastrointestinal side effects is 9%, which increases to between 21% to 37% with metformin and CC combined. However, pregnancy rate is probably improved with metformin and CC. Ovulation rates may be improved with metformin and CC. There was no clear evidence of an effect on miscarriage. </p> <p><b>Metformin versus CC</b> </p> <p>We combined all the studies and found that the quality of evidence was very low, results were inconsistent, and we could not confidently draw conclusions. Obese women had a lower birth rate with metformin, while non‐obese women showed a possible benefit from metformin. The live birth rate of non‐obese women with CC is 26%, which may increase to between 26% and 50% with metformin. However, in obese women, the live birth rate is 22% which may decrease to between 5% to 13% with metformin. Similarly, among obese women taking metformin there may be lower rates of clinical pregnancy and ovulation while, non‐obese women taking metformin may have more pregnancies; there was no clear difference in ovulation rates. We are uncertain whether there is a difference in miscarriage rates between women taking metformin or CC. No studies reported gastrointestinal side effects.<br/> It is possible that a woman's body mass index (a measure of healthy weight based on height and weight) affects which treatment she should take, although further research is required to establish this. The limited improvement in outcomes such as diabetes with metformin highlights the importance of weight loss and lifestyle adjustment, particularly in overweight women with PCOS. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence ranged from very low to moderate. The main problems were that the studies’ methods were poor or unclear, or they did not report all their results (risk of bias), or they were inaccurate and inconsistent. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013505-sec-0184" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013505-sec-0184"></div> <h3 class="title" id="CD013505-sec-0185">Implications for practice</h3> <section id="CD013505-sec-0185"> <p>Our updated review suggests that metformin may be beneficial over placebo for live birth however, more women probably experience gastrointestinal side effects. Compared to placebo, metformin probably increases pregnancy rates and may increase ovulation rates. We are uncertain if metformin plus clomiphene citrate (CC) improves live birth rates compared to CC alone, but gastrointestinal side effects are probably increased with combined therapy. The combined therapy group probably has higher rates of clinical pregnancy and may have higher rates of ovulation. When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence. Results differed by body mass index (BMI), emphasising the importance of stratifying results by BMI. Improved clinical pregnancy and ovulation rates with metformin and CC versus CC alone suggests that combined therapy may be useful although we do not know whether this translates into increased live births. No studies reported gastrointestinal side effects in this comparison. Due to the low quality of the evidence, we are uncertain of the effect of metformin on miscarriage in all three comparisons. </p> </section> <h3 class="title" id="CD013505-sec-0186">Implications for research</h3> <section id="CD013505-sec-0186"> <p>More high‐quality studies are required with adequate power that stratify BMI and CC sensitivity status. Only few studies compared metformin directly with, or in combination with, letrozole and laparoscopic ovarian drilling (LOD), therefore further studies are required to determine the effect these comparisons have on reproductive outcomes. </p> <p>Possible future strategies for insulin‐sensitising drugs include glucagon‐like peptide 1 (GLP‐1) analogues, which have been studied recently in women with PCOS (<a href="./references#CD013505-bbs2-0126" title="JensterleM , KocjanT , PfeiferM , JanezA . Short‐term intervention with liraglutide improved eating behaviour in obese women with polycystic ovary syndrome. Endocrine Research2014;40:133‐8. ">Jensterle 2014</a>). These agents include exenatide and liraglutide and are currently only licensed for the treatment of type 2 diabetes mellitus. One study reported improved pregnancy rates after combined liraglutide and metformin prior to in vitro fertilisation (<a href="./references#CD013505-bbs2-0125" title="JanezA , JensterleM . GLP‐1 receptor agonist liraglutide increased IVF pregnancy rates in obese women with PCOS and previous poor response to first‐line reproductive treatments. Diabetes2018;67 Suppl 1:1465‐P. ">Janez 2018</a>). Future updates of this review may include comparative studies between metformin and these newer agents. Mitochondrial mutations have been associated with insulin resistance and PCOS (<a href="./references#CD013505-bbs2-0114" title="DingY , XiaBH , ZhangCJ , ZhuoGC . Mutations in mitochondrial tRNA genes may be related to insulin resistance in women with polycystic ovary syndrome. American Journal of Translational Research2017;9(6):2984‐96. ">Ding 2017</a>). The development of mitochondrial inhibitors may present an additional new therapeutic strategy for managing PCOS (<a href="./references#CD013505-bbs2-0107" title="ColcaJR , McDonaldWG , CaveyGS , ColeSL , HolewaDD , Brightwell‐ConradAS , et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)‐‐relationship to newly identified mitochondrial pyruvate carrier proteins. PloS One2013 [Epub ahead of print]; Vol. 8. ">Colca 2013</a>; <a href="./references#CD013505-bbs2-0161" title="ZhangY , YeJ . Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharmacologica Sinica2012;2:341‐9. ">Zhang 2012</a>). </p> <p>Future studies of metformin should include live birth rate as the primary outcome. Studies should subdivide data on reproductive outcomes by resistance to CC and BMI (accounting for women having bariatric surgery). The magnitude of insulin resistance is also influenced by ethnicity (<a href="./references#CD013505-bbs2-0102" title="BozdagG , MumusogluS , ZenginD , KarabulutE , YildizBO . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2016;31(12):2841‐55. ">Bozdag 2016</a>). Trials should therefore perform subgroup analyses according to the ethnic origin of participants. These subgroups may reduce the heterogeneity in meta‐analyses. It may be prudent to investigate the efficacy of early intervention in young women or adolescents, or both, with a diagnosis of PCOS. Further data in this area may improve patient selection when determining the appropriate therapeutic strategy. Studies should also focus on the long‐term impact of lifestyle changes and the use of insulin‐sensitising drugs to modulate the risk of developing metabolic syndrome. </p> <p>Good‐quality studies of adequate power are required to investigate the efficacy and safety of any new insulin‐sensitising agents. Although there is no current evidence that metformin is teratogenic (<a href="./references#CD013505-bbs2-0104" title="CassinaM , DonàM , DiGianantonioE , LittaP , ClementiM . First‐trimester exposure to metformin and risk of birth defects: a systematic review and meta‐analysis. Human Reproduction Update2014;20:656‐69. ">Cassina 2014</a>), if it is used widely to treat anovulation then it is possible that rare effects may be unmasked. Metformin therapy therefore needs to be kept under continuing surveillance with more stringent reporting of adverse outcomes including gastrointestinal side effects. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013505-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013505-sec-0029"></div> <div class="table" id="CD013505-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : women with polycystic ovary syndrome<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000<br/> (188 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> (1.00 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>302 per 1000 (221 to 397)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.00</b> </p> <p>(2.63 to 6.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<sup>2</sup> = 39% due to 1 study <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000 (210 to 323)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.98</b> </p> <p>(1.47 to 2.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1213<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per</p> <p>1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000 (371 to 545)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.64</b> </p> <p>(1.85 to 3.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 61% (82% in non‐obese group) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> <p>(20 to 89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b><br/> (0.50 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy: OR 0.58, 95% CI 0.25 to 1.34; 200 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to report methods of randomisation and/or serious risk of attrition bias in some of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as the event rate is low and findings are compatible with benefit in one or both groups or with no meaningful difference between the groups.<br/> <sup>c</sup>Moderate inconsistency (I<sup>2</sup> = 39%), but not downgraded, as all heterogeneity is attributable to a single small study and the direction of effect largely consistent.<br/> <sup>d</sup>Downgraded one level for serious inconsistency (I<sup>2</sup> = 62%) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013505-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting</b> : outpatient<br/> <b>Intervention</b> : metformin combined with ovulation induction agent clomiphene citrate<br/> <b>Comparison</b>: Clomiphene citrate alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CC alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin combined with CC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>281 per 1000</p> <p>(232 to 337)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.27</b> </p> <p>(0.98 to 1.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1219<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> <p>(208 to 372)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.26</b><br/> (2.83 to 6.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>852<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>383 per 1000</p> <p>(336 to 432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.62</b><br/> (1.32 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1790<br/> (19 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>629 per 1000</p> <p>(581 to 676)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.65</b> </p> <p>(1.35 to 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1601<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>101 per 1000</p> <p>(70 to 142)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.35</b><br/> (0.91 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy: OR 1.07 95% CI 0.69 to 1.66; 471 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CC:</b> clomiphene citrate; <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to describe study methods and/or serious risk of attrition bias in several of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as findings are compatible with benefit in one or both groups or with no meaningful difference between the group.<br/> <sup>c</sup>Some evidence of imprecision seen in obese group however only one study included therefore not downgraded, given clear effect seen in BMI &lt; 30 kg/m<sup>2</sup> group.<br/> <sup>d</sup>High heterogeneity (I<sup>2</sup> = 63%), but not downgraded as direction of effect consistent and most inconsistency is due to a single small study.<br/> <sup>e</sup>Downgraded one level for evidence of publication bias seen with three studies outside the funnel plot and asymmetry around the line of effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013505-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting:</b> outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: clomiphene citrate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> <p><sup>a</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> <p>(256 to 503)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> (1.00 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High heterogeneity (I<sup>2</sup> = 78%) </p> <p>76 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> <p>(45 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b> </p> <p>(0.17 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>(gastrointestinal)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b><sup>a</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000 (270 to 444)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b><br/> (1.06 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000 (74 to 173)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.34</b><br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p><sup>f</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>650 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597 per 1000 (491 to 699)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.80</b><br/> (0.52 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p><sup>f</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1,000<br/> (176 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b><br/> (0.20 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> <p><sup>a</sup>Participants with BMI &lt; 30 kg/<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000 (36 to 182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.51</b> (0.62 to 3.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 events</p> <p>Miscarriage rate per pregnancy: OR 1.02 (0.41 to 2.54)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000 (18 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.61</b> (0.27 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 events; only 1 study with events</p> <p>Miscarriage rate per pregnancy: OR 1.92 (0.72 to 5.12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> &gt; 85%) with differing directions of effect.<br/> <sup>b</sup>Evidence downgraded one level for risk of bias.<br/> <sup>c</sup>Evidence downgraded one level for serious imprecision: low event rate and/or wide confidence intervals.<br/> <sup>d</sup>Evidence downgraded for high heterogeneity.<br/> <sup>e</sup>Evidence downgraded for serious imprecision; many small studies with wide confidence intervals.<br/> <sup>f</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> = 74%), though direction of effect was consistent. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013505-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013505-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013505-sec-0216">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD013505-sec-0030"></div> <section id="CD013505-sec-0031"> <h3 class="title" id="CD013505-sec-0031">Description of the condition</h3> <p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting at least 8% to 13% of women of reproductive age (<a href="./references#CD013505-bbs2-0102" title="BozdagG , MumusogluS , ZenginD , KarabulutE , YildizBO . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2016;31(12):2841‐55. ">Bozdag 2016</a>; <a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>; <a href="./references#CD013505-bbs2-0154" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , et al. International PCOS Network. Recommendations from the international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility2018;110(3):364‐79. ">Teede 2018</a>). The disorder is heterogeneous, encompassing a broad spectrum of signs and symptoms of ovarian dysfunction. The classic presentation, as described by Stein and Leventhal (<a href="./references#CD013505-bbs2-0152" title="SteinIF . Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology1935;29:181‐91. ">Stein 1935</a>), with features of obesity, amenorrhoea and hirsutism is one end of the spectrum that, at the other end, includes women with normal menstrual cyclicity and yet with ultrasound, evidence of a polycystic ovarian appearance (<a href="./references#CD013505-bbs2-0118" title="FauserBC , TarlatzisBC , RebarRW , LegroRS , BalenAH , LoboR , et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM‐sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility2012;97:28‐38. [PUBMED: 22153789] ">Fauser 2012</a>). Therefore, no single diagnostic criterion (such as hyperandrogenism or polycystic ovaries (PCO)) is sufficient for the clinical diagnosis. The 2003 Rotterdam Consensus' revised diagnostic criteria for a diagnosis of PCOS are as follows, with two of the following being required: <br/>1. oligo or anovulation, or both, that is, menstrual disturbance; <br/>2. clinical or biochemical signs, or both, of hyperandrogenism; <br/>3. PCO on ultrasound; and exclusion of other aetiologies of menstrual disturbance and hyperandrogenism (such as congenital adrenal hyperplasia, androgen‐secreting tumours, Cushing's syndrome) (<a href="./references#CD013505-bbs2-0115" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). A recent update to guidelines in view of advancing ultrasound technology and resolution, state that the diagnostic criteria for ultrasound PCO morphology is either 20 or more follicles per ovary or increased ovarian volume, over 10 mL, when using a transvaginal ultrasound scan (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). </p> <p>Although PCOS is the commonest cause of anovulatory infertility (<a href="./references#CD013505-bbs2-0098" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>), up to 70% of women with PCOS remain undiagnosed (<a href="./references#CD013505-bbs2-0132" title="MarchWA , MooreVM , WillsonKJ , PhillipsDI , NormanRJ , DaviesMJ . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction2010;25:544‐51. ">March 2010</a>). </p> <p>The expression of PCOS symptoms is multifaceted, and the reduced conception rates associated with PCOS may be related to hyperandrogenism, obesity and insulin resistance (<a href="./references#CD013505-bbs2-0098" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>). Over the last 20 years, the body of evidence indicating that increased insulin resistance and compensatory high insulin concentrations (hyperinsulinaemia) play a key role in the pathogenesis of PCOS has grown (<a href="./references#CD013505-bbs2-0098" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>; <a href="./references#CD013505-bbs2-0145" title="RubinKH , GlintborgD , NyboM , AbrahamsenB , AndersenM . Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2017;102(10):3848‐57. ">Rubin 2017</a>). Insulin resistance is more common in overweight women but can also occur in non‐obese women with the disorder (<a href="./references#CD013505-bbs2-0103" title="CassarS , MissoML , HopkinsWG , ShawCS , TeedeHJ , SteptoNK . Insulin resistance in polycystic ovary syndrome: a systematic review and meta‐analysis of euglycaemic‐hyperinsulinaemic clamp studies. Human Reproduction2016;31(11):2619‐31. ">Cassar 2016</a>). </p> <p>The insulin resistance associated with PCOS can worsen both women's symptom profile and their likelihood of achieving a live birth (<a href="./references#CD013505-bbs2-0103" title="CassarS , MissoML , HopkinsWG , ShawCS , TeedeHJ , SteptoNK . Insulin resistance in polycystic ovary syndrome: a systematic review and meta‐analysis of euglycaemic‐hyperinsulinaemic clamp studies. Human Reproduction2016;31(11):2619‐31. ">Cassar 2016</a>). Women with insulin resistance have a significantly higher level of testosterone and increased prevalence of hirsutism than women with non‐insulin‐resistant PCOS (<a href="./references#CD013505-bbs2-0097" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroR , et al. Polycystic ovary syndrome. Nature2016;2:1‐18. ">Azziz 2016</a>). Insulin‐resistant women with PCOS also have a lower ovulation rate and are more likely to develop resistance to ovulation induction with clomiphene citrate (CC) compared with women with non‐insulin resistant PCOS. Lifestyle modification including weight loss and exercise reduces central fat and improves insulin sensitivity, restoring ovulation in overweight, infertile women with PCOS (<a href="./references#CD013505-bbs2-0097" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroR , et al. Polycystic ovary syndrome. Nature2016;2:1‐18. ">Azziz 2016</a>). </p> <p>The impaired glucose tolerance results can predispose women to the development of type 2 diabetes mellitus compared with the background population (<a href="./references#CD013505-bbs2-0106" title="CelikC , TasdemirN , AbaliR , BastuE , YilmazM . Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow‐up study. Fertility and Sterility2014;101:1123‐8. ">Celik 2014</a>). <a href="./references#CD013505-bbs2-0106" title="CelikC , TasdemirN , AbaliR , BastuE , YilmazM . Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow‐up study. Fertility and Sterility2014;101:1123‐8. ">Celik 2014</a> conducted a prospective study of insulin resistance in 84 women with PCOS, with a mean follow‐up period of 2.6 years. Of those with normal glucose tolerance, 11.5% converted to insulin resistance (annual incidence rate 4.5%). This compares to 2.3% in the healthy control population (n = 45), with an annual progression of 0.9%. For women with impaired glucose tolerance at the outset, 33.3% developed diabetes (annual incidence rate 10.4%).<br/> <br/> The prevalence of insulin resistance in women with PCOS is influenced by body mass index (BMI) and at least 50% of women with PCOS are obese (<a href="./references#CD013505-bbs2-0098" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>; <a href="./references#CD013505-bbs2-0103" title="CassarS , MissoML , HopkinsWG , ShawCS , TeedeHJ , SteptoNK . Insulin resistance in polycystic ovary syndrome: a systematic review and meta‐analysis of euglycaemic‐hyperinsulinaemic clamp studies. Human Reproduction2016;31(11):2619‐31. ">Cassar 2016</a>). Correspondingly, a Mexican study found an increased prevalence of insulin resistance in obese women with PCOS compared to normal‐weight women with PCOS (78.2% and 19.3% respectively; <a href="./references#CD013505-bbs2-0144" title="Reyes‐MunozE , Ortega‐GonzalezC , Martinez‐CruzN , Arce‐SanchezL , Estrada‐GutierrezG , MoranC , et al. Association of obesity and overweight with the prevalence of insulin resistance, pre‐diabetes and clinical–biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross‐sectional study. BMJ Open2016;6:1‐8. ">Reyes‐Munoz 2016</a>). Obesity, and particularly abdominal obesity as indicated by an increased waist to hip ratio, is correlated with reduced fecundity (<a href="./references#CD013505-bbs2-0150" title="SilvestrisE , dePergolaG , RosaniaR , LoverroG . Obesity as a disruptor of the female fertility. Reproductive Biology and Endocrinology2018;16:1‐13. ">Silvestris 2018</a>). A small study demonstrated increased preterm birth and low birth‐weight infants in obese versus normal‐weight women with PCOS (<a href="./references#CD013505-bbs2-0109" title="DeFrèneV , VansteelandtS , T'SjoenG , GerrisJ , SomersS , VercruysseL , et al. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Human Reproduction2014;29:2333‐8. ">De Frene 2014</a>). Weight loss has been shown to improve the endocrine profile, menstrual cyclicity and the likelihood of ovulation (<a href="./references#CD013505-bbs2-0150" title="SilvestrisE , dePergolaG , RosaniaR , LoverroG . Obesity as a disruptor of the female fertility. Reproductive Biology and Endocrinology2018;16:1‐13. ">Silvestris 2018</a>). Meta analyses have found that weight loss reduced testosterone and insulin resistance as well as improving reproductive outcomes (<a href="./references#CD013505-bbs2-0135" title="MoranLJ , HutchisonSK , NormanRJ , TeedeHJ . Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD007506.pub3] ">Moran 2011</a>; <a href="./references#CD013505-bbs2-0151" title="SimKA , PartridgeSR , SainsburyA . Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review. Obesity Reviews2014;15:839‐50. ">Sim 2014</a>).<br/> <br/> There is therefore considerable overlap between metabolic syndrome and the metabolic disturbances that feature in PCOS. Metabolic syndrome is a cluster of risk factors that confer an increased risk for cardiovascular disease and type II diabetes (<a href="./references#CD013505-bbs2-0134" title="MoranLJ , MissoML , WildRA , NormanRJ . Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2010;16:347‐63. ">Moran 2010</a>). Women with metabolic syndrome may have a higher mortality from cardiovascular disease overall, coronary heart disease and stroke compared with women without the syndrome (<a href="./references#CD013505-bbs2-0134" title="MoranLJ , MissoML , WildRA , NormanRJ . Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2010;16:347‐63. ">Moran 2010</a>). The prevalence of metabolic syndrome among women with PCOS was increased compared to the general population (OR 2.20, 95% CI 1.36 to 3.56 for BMI‐matched studies; <a href="./references#CD013505-bbs2-0134" title="MoranLJ , MissoML , WildRA , NormanRJ . Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2010;16:347‐63. ">Moran 2010</a>). Women with PCOS are four times more likely to develop type 2 diabetes mellitus and be diagnosed four years earlier compared with non‐PCOS women (<a href="./references#CD013505-bbs2-0145" title="RubinKH , GlintborgD , NyboM , AbrahamsenB , AndersenM . Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2017;102(10):3848‐57. ">Rubin 2017</a>). The prevalence also varies amongst different ethnic groups, which is likely to be influenced by the background prevalence of insulin resistance (<a href="./references#CD013505-bbs2-0102" title="BozdagG , MumusogluS , ZenginD , KarabulutE , YildizBO . The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction2016;31(12):2841‐55. ">Bozdag 2016</a>). Furthermore, women with PCOS and metabolic syndrome tend to have a higher BMI, which has an increased risk of developing complications such as hypertension, insulin resistance, metabolic syndrome and endometrial hyperplasia (<a href="./references#CD013505-bbs2-0146" title="SachdevaG , GainderS , SuriV , SachdevaN , ChopraS . Obese and non‐obese polycystic ovarian response: comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian Journal of Endocrinology and Metabolism2019;23(2):257‐62. ">Sachdeva 2019</a>). PCOS therefore affects reproductive outcomes and confers significant long‐term health risks to women. PCOS also has a significant psychological impact and is associated with low self‐esteem, anxiety and depression (<a href="./references#CD013505-bbs2-0136" title="MoranLJ , DeeksAA , Gibson‐HelmME , TeedeHJ . Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction2012;27:2082‐8. ">Moran 2012</a>).<br/> <br/> With the increasing prevalence of obesity in society, the prevalence of PCOS is likely to rise. There are therefore significant financial implications for the funding of PCOS management by healthcare providers. A 2005 study calculated approximately USD 4.36 billion are spent on managing reproductive‐age women with PCOS, of which USD 533 million is related to infertility (<a href="./references#CD013505-bbs2-0096" title="AzzizR , MarinC , HoqL , BadamgaravE , SongP . Health care‐related economic burden of the polycystic ovary syndrome during the reproductive life span. Journal of Clinical Endocrinology and Metabolism2005;90:4650‐8. ">Azziz 2005</a>; <a href="./references#CD013505-bbs2-0097" title="AzzizR , CarminaE , ChenZ , DunaifA , LavenJS , LegroR , et al. Polycystic ovary syndrome. Nature2016;2:1‐18. ">Azziz 2016</a>). </p> </section> <section id="CD013505-sec-0032"> <h3 class="title" id="CD013505-sec-0032">Description of the intervention</h3> <p>Metformin is an antihyperglycaemic biguanide drug, widely used for the treatment of type 2 diabetes mellitus. However, the exact mechanism of action through which metformin has its glucose‐lowering effect is still being explored (<a href="./references#CD013505-bbs2-0140" title="PernicovaI , KorbonitsM . Metformin‐‐mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology2014;10:143‐56. [DOI: 10.1038/nrendo.2013.256] ">Pernicova 2014</a>). Metformin inhibits hepatic gluconeogenesis and reduces the action of glucagon, resulting in a reduction in circulating insulin and glucose. This is thought to occur via inhibition of mitochondrial complexes with downstream effects on cyclic adenosine monophosphate (AMP) and protein kinase signalling pathways. The effect on protein kinase may also modulate lipid synthesis. Metformin is known to exert its effect on several tissues affected by insulin resistance, including the liver, adipose tissue and the ovaries (<a href="./references#CD013505-bbs2-0140" title="PernicovaI , KorbonitsM . Metformin‐‐mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology2014;10:143‐56. [DOI: 10.1038/nrendo.2013.256] ">Pernicova 2014</a>). </p> <p>We compared metformin with three alternative forms of ovulation induction: CC, letrozole and laparoscopic ovarian drilling (LOD). </p> <p>CC is an anti‐oestrogen often used first line to induce ovulation (<a href="./references#CD013505-bbs2-0099" title="BalenAH . Polycystic ovary syndrome (PCOS). Obstetrician &amp; Gynaecologist2017;19:119‐29. ">Balen 2017</a>). CC is commenced on day two to five of the menstrual cycle, after pregnancy has been excluded, and given for five days. All women who are given CC are monitored by serial ultrasound assessments of follicular growth and if no menstruation by day 35, a withdrawal bleed is induced. Adverse effects of CC include luteinizing hormone (LH) hypersecretion, which reduces conception rates and increases miscarriage rates, possibly due to the anti‐oestrogen effects on the endometrium and cervical mucus (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). CC can also lead to increased rates of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS), and therefore close ultrasound surveillance is required. </p> <p>Letrozole is an aromatase inhibitor, used for ovulation induction (<a href="./references#CD013505-bbs2-0099" title="BalenAH . Polycystic ovary syndrome (PCOS). Obstetrician &amp; Gynaecologist2017;19:119‐29. ">Balen 2017</a>). Letrozole inhibits the aromatisation of androgens to oestrogen and hence reduces the negative feedback otherwise induced by oestrogen on the hypothalamic‐pituitary axis. Rising levels of follicle‐stimulating hormone (FSH) leads to stimulation of follicle development, follicle maturation, and ovulation (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). Improved pregnancy and live birth rates have been reported with letrozole, and reduced incidence of multiple pregnancy compared with CC (<a href="./references#CD013505-bbs2-0120" title="FranikS , KremerJA , NelenW , FarquharC . Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010287.pub2] ">Franik 2014</a>). However, concerns have risen regarding the possible association between letrozole use and congenital malformations (<a href="./references#CD013505-bbs2-0100" title="BiljanMM , HemmingsR , BrassardN . The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertility and Sterility2005;84(Supp 1):S95. ">Biljan 2005</a>). The World Health Organization (WHO) does support the use of letrozole as first‐line treatment for ovulation induction although many countries insist that more research on safety and efficacy is required (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). </p> <p>LOD is the surgical method of ovulation induction that has replaced the previous method of laparotomy and ovarian wedge resection (<a href="./references#CD013505-bbs2-0099" title="BalenAH . Polycystic ovary syndrome (PCOS). Obstetrician &amp; Gynaecologist2017;19:119‐29. ">Balen 2017</a>). LOD can be performed using monopolar, bipolar or laser diathermy to four separate points per ovary. This reduces LH and testosterone levels, leading to a resumption of regular menses. LOD provides an alternative treatment for women with CC resistance or for women who cannot be closely monitored for CC induction (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). LOD may also be appropriate for women undergoing laparoscopic assessment of the pelvis for an alternative reason. A previous Cochrane Review compared the efficacy of LOD with combined metformin and CC and concluded that there was evidence of fewer live births in women with CC‐resistant PCOS undergoing LOD compared to metformin and CC (<a href="./references#CD013505-bbs2-0117" title="FarquharC , BrownJ , MarjoribanksJ . Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews2012, (6):1‐73. ">Farquhar 2012</a>). </p> </section> <section id="CD013505-sec-0033"> <h3 class="title" id="CD013505-sec-0033">How the intervention might work</h3> <p>Increased insulin resistance, hyperandrogenism and obesity have a significant impact on menstrual cyclicity and reproductive health (<a href="./references#CD013505-bbs2-0146" title="SachdevaG , GainderS , SuriV , SachdevaN , ChopraS . Obese and non‐obese polycystic ovarian response: comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian Journal of Endocrinology and Metabolism2019;23(2):257‐62. ">Sachdeva 2019</a>). Metformin may therefore have beneficial effects on anovulatory infertility in PCOS, with reduced hepatic glucose production, reduced levels of circulating insulin acting on the ovaries and restoration of ovarian function (<a href="./references#CD013505-bbs2-0158" title="ViolletB , GuigasB , Sanz GarciaN , LeclercJ , ForetzM , AndreelliF . Cellular and molecular mechanisms of metformin: an overview. Clinical Science (London, England : 1979)2012;122(6):253‐70. ">Viollet 2012</a>). Within the ovary itself, metformin may also have a direct impact on cells to reduce excessive steroidogenesis and follicular growth (<a href="./references#CD013505-bbs2-0112" title="Diamanti‐KandarakisE , ChristakouCD , KandarakisE , EconomouF . Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology2010;162:193‐212. ">Diamanti‐Kandarakis 2010</a>). Metformin has been shown to reduce theca cell proliferation, reduce the number of small follicles and cysts, yet have higher percentages of antral follicles and corpora lutea, hence improving the chance of ovulation (<a href="./references#CD013505-bbs2-0111" title="DiPetroM , ParborellF , IrustaG , PascualiN , BasD , BianchiMS , et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology2015;156(4):1453‐63. ">Di Petro 2015</a>). </p> <p>As insulin resistance and resulting hyperinsulinaemia are key metabolic features in women with PCOS, their amelioration through metformin could improve PCOS‐associated symptoms and conception rates. </p> </section> <section id="CD013505-sec-0034"> <h3 class="title" id="CD013505-sec-0034">Why it is important to do this review</h3> <p>This is an updated Cochrane Review focusing on the impact of metformin on the reproductive outcomes in women with PCOS‐related subfertility, compared to or in combination with CC, letrozole and LOD. This follows on from previous reviews comparing the effects of metformin with thiazolidinediones including troglitazone, rosiglitazone and pioglitazone (first published in 2003 and most recently updated in 2017 (<a href="./references#CD013505-bbs2-0131" title="LordJ , WilkinT . Polycystic ovary syndrome and fat distribution: the central issue?. Human Fertility (Cambridge)2002;5:67‐71. ">Lord 2002</a>; <a href="./references#CD013505-bbs2-0164" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>; <a href="./references#CD013505-bbs2-0165" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] ">Tang 2012</a>; <a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>). However, the most recent update in 2017 found insufficient evidence of benefit with thiazolidinediones and furthermore there has been a withdrawal of thiazolidinediones from the market due to adverse effects on liver function (<a href="./references#CD013505-bbs2-0119" title="FDA (Federal Drug Administration). www.fda.gov Accessed 12 November 2019. ">FDA 2019</a>). As a result we have excluded thiazolidinediones from this review. </p> <p>The most recent 2017 update focused on live birth rate as the primary outcome. Metformin alone was found to be of benefit when compared with placebo, although the overall quality of evidence was low (<a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>). The live birth rate when comparing metformin versus CC was inconclusive. However, an improvement in clinical pregnancy and ovulation rates was observed with CC compared with metformin in obese women with PCOS. Results of this review differed by BMI and also by resistance to CC and maternal age. In addition, many older studies did not record live birth rate as an outcome. Anthropometric outcomes were included in the previous reviews, although these were documented inconsistently in the studies. </p> <p>There is therefore scope for a Cochrane Review focusing on the reproductive outcomes in women being treated with metformin. We compared the efficacy of metformin versus alternative ovulation induction agents including CC, letrozole and LOD. A previous Cochrane Review looked specifically at gonadotrophins for ovulation induction in women with PCOS and therefore we excluded gonadotrophin therapy as a comparison from this review (<a href="./references#CD013505-bbs2-0101" title="BordewijkEM , NahuisM , CostelloMF , Van derVeenF , TsoLO , MolBW , et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD009090.pub2] ">Bordewijk 2017</a>). The primary outcome of this review was the most important clinical end point, live birth rate. Subgroup analysis by BMI, maternal age and CC resistance, including high‐quality studies, will shed further light on the best management practice for anovulatory infertility. </p> <p>Details of abbreviations used in this review and conversion factors of biochemical results can be found in <a href="#CD013505-tbl-0004">Table 1</a> and <a href="#CD013505-tbl-0005">Table 2</a>, respectively. </p> <div class="table" id="CD013505-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body mass index</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computerised tomography scan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follicle‐stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose tolerance test</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycosylated haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laparoscopic ovarian drilling</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIDDM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non insulin dependent diabetes mellitus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised controlled trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant follicle‐stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error of the mean</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Versus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013505-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert from</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert to</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conversion factor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013505-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013505-sec-0035"></div> <p>To evaluate the effectiveness and safety of metformin in combination with or in comparison to clomiphene citrate (CC), letrozole and laparoscopic ovarian drilling (LOD) in improving reproductive outcomes and associated gastrointestinal side effects for women with PCOS undergoing ovulation induction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013505-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013505-sec-0036"></div> <section id="CD013505-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013505-sec-0038"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) were eligible for inclusion. We excluded non‐randomised and quasi‐randomised studies due to the high risk of bias. We included cross‐over studies but we only included data from the first phase of meta‐analyses. </p> </section> <section id="CD013505-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included women with oligo and anovulatory PCOS, based on the diagnostic criteria set by the Rotterdam Consensus (<a href="./references#CD013505-bbs2-0115" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>), undergoing ovulation induction. We excluded women having in vitro fertilisation (IVF) or intracytoplasmic spermatic injection (ICSI), as this is covered in a separate Cochrane Review (<a href="./references#CD013505-bbs2-0155" title="TsoL , CostelloMF , AlbuquerqueLE , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>). </p> </section> <section id="CD013505-sec-0040"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD013505-list-0001"> <li> <p>Metformin versus placebo or no treatment</p> </li> <li> <p>Metformin and CC versus CC</p> </li> <li> <p>Metformin versus CC</p> </li> <li> <p>Metformin and letrozole versus letrozole</p> </li> <li> <p>Metformin versus letrozole</p> </li> <li> <p>Metformin and LOD versus LOD</p> </li> <li> <p>Metformin versus LOD</p> </li> </ol> </p> <p>We excluded thiazolidinediones (troglitazone, rosiglitazone and pioglitazone) because of the concerns about adverse effects such as hepatotoxicity, heart failure and bladder cancer leading to their subsequent withdrawal from the market (<a href="./references#CD013505-bbs2-0119" title="FDA (Federal Drug Administration). www.fda.gov Accessed 12 November 2019. ">FDA 2019</a>). The last update of this review found insufficient evidence of a benefit of thiazolidinediones for ovulation induction (<a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>). </p> </section> <section id="CD013505-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD013505-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>1. Live birth rate, as defined by included studies</p> <p>2. Gastrointestinal side effects</p> </section> <section id="CD013505-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>3. Clinical pregnancy rate, as defined by included studies (biochemical pregnancies were excluded) </p> <p>4. Ovulation rate, as defined by included studies</p> <p>5. Miscarriage rate</p> <p>6. Multiple pregnancy rate</p> <p>7. Anthropometric outcomes: BMI</p> <p>8. Endocrine outcomes</p> <p>a) Serum testosterone</p> <p>b) Serum sex hormone‐binding globulin</p> <p>9. Metabolic outcomes</p> <p>a) Fasting blood glucose</p> <p>b) Fasting insulin</p> </section> </section> </section> <section id="CD013505-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs without language restriction and in consultation with Cochrane Gynaecology and Fertility (CGF) Information Specialist. The original search was conducted in 2003, which included metformin and other insulin sensitisers compared with placebo or CC in PCOS. The first updated search was completed on 11 September 2008, the second update was completed on 3 October 2011, the third update was completed on 12 January 2017. The current search was completed on 13 December 2018 and included metformin only. </p> <section id="CD013505-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched:</p> <p> <ol id="CD013505-list-0002"> <li> <p>CGF Specialised Register of Controlled Trials, PROCITE platform (searched 13 December 2018; <a href="./appendices#CD013505-sec-0190">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 12) via the Cochrane Register of Studies Online (CRSO) Web platform (<a href="./appendices#CD013505-sec-0191">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (searched from 1946 to 13 December 2018; <a href="./appendices#CD013505-sec-0192">Appendix 3</a>); </p> </li> <li> <p>Embase Ovid (searched from 1980 to 13 December 2018; <a href="./appendices#CD013505-sec-0193">Appendix 4</a>); </p> </li> <li> <p>PsycINFO Ovid (searched form 1806 to 13 December 2018; <a href="./appendices#CD013505-sec-0194">Appendix 5</a>); and </p> </li> <li> <p>CINAHL EBSCO platform (searched from 1961 to 13 December 2018; <a href="./appendices#CD013505-sec-0195">Appendix 6</a>). </p> </li> </ol> </p> <p>We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials, which appears in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD013505-bbs2-0129" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). The Embase, PsycINFO and CINAHL searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) <a href="http://www.sign.ac.uk/search-filters.html" target="_blank">www.sign.ac.uk/search‐filters.html</a>. </p> <p>Other electronic sources of trials included:</p> <p> <ol id="CD013505-list-0003"> <li> <p>trials registers for ongoing and registered trials;</p> <ol id="CD013505-list-0004"> <li> <p><a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>; </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">ICTRP</a>); </p> </li> </ol> </li> </ol> </p> <p> 2. PubMed and Google Scholar for recent trials not yet indexed in MEDLINE.</p> </section> <section id="CD013505-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference sections of all studies obtained. In liaison with the CGF Information Specialist we searched relevant journal articles and conference abstracts that are not covered in the CGF register. We contacted study authors and experts in the field to identify additional studies. </p> </section> </section> <section id="CD013505-sec-0047"> <h3 class="title" id="CD013505-sec-0047">Data collection and analysis</h3> <section id="CD013505-sec-0048"> <h4 class="title">Selection of studies</h4> <p>The first review of this subject (<a href="./references#CD013505-bbs2-0162" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a>), was undertaken by three review authors (JML, IHF and RJN), two of whom work in reproductive medicine (JML, RJN). Three review authors (TT, EY, AHB) updated the review (<a href="./references#CD013505-bbs2-0164" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>; <a href="./references#CD013505-bbs2-0165" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] ">Tang 2012</a>). Three review authors (LCM, TT and AHB) performed the last update (<a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>). Five review authors (ANS, LCM, TT, RN and AHB) performed the current update. We employed the search strategy described previously to obtain titles and, where possible, relevant study abstracts. Two review authors (ANS and LCM) screened the titles and abstracts and then obtained copies of the relevant full‐text articles. Two review authors (ANS and LCM) independently assessed whether the studies met the inclusion criteria, with disagreements resolved by discussion with a third author (TT). For details of the screening and selection process see <a href="#CD013505-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013505-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram 2019 update" data-id="CD013505-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram 2019 update</p> </div> </div> </div> </section> <section id="CD013505-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (ANS and LCM) independently extracted data from eligible studies onto a pre‐designed form, and resolved any disagreements by discussion with a third author (TT). Data extracted includes study characteristics and outcome data. We sought further information from the study authors where papers contained insufficient information. </p> <p>Some studies were multi‐arm studies, and we excluded data from arms that did not meet the study criteria. </p> </section> <section id="CD013505-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ANS and LCM) independently assessed the risk of bias in accordance with the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD013505-bbs2-0124" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <p>We assessed selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias and summarised our judgements in the 'Risk of bias' tables, <a href="#CD013505-fig-0002">Figure 2</a> and <a href="#CD013505-fig-0003">Figure 3</a>. We resolved disagreements by discussion. We incorporated the assessment of bias judgements into the interpretation of review findings by means of sensitivity analyses. </p> <div class="figure" id="CD013505-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD013505-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD013505-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013505-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> </section> <section id="CD013505-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We used odds ratio (OR) as the measure of effect for each dichotomous outcome and the mean difference (MD) for each continuous outcome. We have presented 95% confidence intervals (CI) for all outcomes. </p> </section> <section id="CD013505-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The primary unit of analysis was each woman. For example, we calculated ovulation rate as rate of women in whom ovulation was confirmed. Where studies reported 'per‐cycle' data, we contacted the study authors to request 'per‐woman' data. When these data were not available, we did not pool the per‐cycle ovulation data but presented them in additional tables (<a href="#CD013505-tbl-0006">Table 3</a>; <a href="#CD013505-tbl-0007">Table 4</a>; <a href="#CD013505-tbl-0008">Table 5</a>; <a href="#CD013505-tbl-0009">Table 6</a>; <a href="#CD013505-tbl-0010">Table 7</a>). The exceptions to this were miscarriage and multiple pregnancy rates, which we analysed per woman, followed by a sensitivity analysis using per‐pregnancy data. </p> <div class="table" id="CD013505-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin versus placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013505-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin and clomiphene citrate versus clomiphene citrate alone: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin +<br/> clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013505-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin versus clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.32</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013505-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metformin and letrozole vs letrozole: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin and letrozole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Letrozole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013505-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Metformin and laparoscopic ovarian drilling (LOD) vs LOD: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin &amp; LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> </div> <p>In order to reduce a carry‐over of treatment effect in cross‐over trials, we only used data from the first phase (such as before cross‐over) when the washout period was less than two months. The rationale is that oligo amenorrhoea is usually accepted as a menstrual cycle length over five to eight weeks. Therefore, the washout period of treatment effect on ovulation should ideally be more than eight weeks. </p> </section> <section id="CD013505-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat basis where possible and sought any missing data from the study authors. </p> <p>When this information was not available, we performed the analysis using the original number of women randomised. </p> </section> <section id="CD013505-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity reflects any type of variability among the studies in a systematic review. A consistent treatment effect among the included studies suggests there is sufficient homogeneity for pooled analysis. We used the I<sup>2</sup> statistic (<a href="./references#CD013505-bbs2-0123" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), to quantify the inconsistency among the studies. We regarded an I<sup>2</sup> statistic of over 50% as indicative of substantial heterogeneity (<a href="./references#CD013505-bbs2-0110" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD013505-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise the potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we produced funnel plots for the primary outcome live birth, to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies; <a href="./references#CD013505-bbs2-0153" title="SterneJA , EggerM , MoherD , BoutronI (editors) . Chapter10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Sterne 2017</a>). </p> </section> <section id="CD013505-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses according to the statistical guidelines for review authors developed by Cochrane and published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013505-bbs2-0110" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). We used Review Manager 5 (RevMan 5) to perform all the statistical analyses (<a href="./references#CD013505-bbs2-0143" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>We used OR, with 95% CI, as the measure of effect for each dichotomous outcome using the Mantel‐Haenszel method; whilst we presented continuous outcome differences between the two groups as MD with 95% CI. We employed a fixed‐effect model in the analysis, and have commented on significant heterogeneity where it occurred. </p> <p>For clinical outcomes, we stratified comparisons by BMI, divided into obese and non‐obese groups, with an additional stratum for studies in which BMI was not reported. We defined 'obese' as BMI equal to or over 30 kg/m<sup>2</sup>. </p> </section> <section id="CD013505-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As noted above, we subgrouped the primary analysis by BMI (obese or non‐obese), in order to assess any differences in effect within these subgroups. </p> <p>We also conducted subgroup analyses by sensitivity to CC (sensitive or resistant), in relevant analyses (i.e. including CC group) where substantial heterogeneity was detected (I<sup>2</sup> over 50%). </p> <p>We also planned to explore other possible explanations where heterogeneity was substantial, by examining other clinical or methodological differences between the studies. </p> </section> <section id="CD013505-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>To determine that the conclusions of this review were robust, we performed sensitivity analyses after excluding studies with unclear or high risk of bias in sequence generation, allocation concealment or blinding method. We also performed a sensitivity analysis to compare the effect of reporting miscarriage and multiple pregnancy data 'per pregnancy'. </p> <section id="CD013505-sec-0059"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared 'Summary of findings' tables using GRADEpro GDT software (<a href="./references#CD013505-bbs2-0122" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 2015‐2017. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>). These tables evaluated the overall quality of the body of evidence for the main review outcomes (live birth, adverse events, clinical pregnancy, ovulation and miscarriage) with respect to the most clinically relevant comparisons (metformin versus placebo or no treatment, metformin and CC versus CC alone, metformin versus CC). Two review authors working independently evaluated the quality of the evidence using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). We justified and documented our judgements about evidence quality (high, moderate, low or very low) and incorporated them into reporting of results for each outcome (<a href="./references#CD013505-bbs2-0147" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. ">Schünemann 2013</a>; <a href="./references#CD013505-bbs2-0148" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). We resolved any disagreements by consensus. </p> <p>The previous update found a high heterogeneity when metformin was compared with CC for some outcomes, which was associated with BMI status. In this review, we have presented the data by BMI subgroup. </p> <p>Details of abbreviations used in this review and conversion factors of biochemical results can be found in <a href="#CD013505-tbl-0004">Table 1</a> and <a href="#CD013505-tbl-0005">Table 2</a>, respectively. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013505-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013505-sec-0060"></div> <section id="CD013505-sec-0061"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013505-sec-0212" title="">Characteristics of included studies</a> and <a href="./references#CD013505-sec-0213" title="">Characteristics of excluded studies</a> for full details of the studies. </p> <section id="CD013505-sec-0062"> <h4 class="title">Results of the search</h4> <p>In this updated review there are 41 included studies and 42 excluded studies (<a href="#CD013505-fig-0001">Figure 1</a>). </p> <p>In this current update (fourth update, search period up to December 2018), we introduced changes to exclude thiazolidinediones and to include metformin compared with CC, letrozole and LOD. We included only studies that reported reproductive outcomes. We performed a new search up to December 2018. We considered the full texts of 94 articles (66 new studies and 28 studies from the previous review). Of these, we excluded 42 studies, five are ongoing clinical trials with no published results (<a href="./references#CD013505-bbs2-0090" title="NCT00005104 . Randomized study of decreased hyperinsulinemia on the ovulatory response to clomiphene citrate in women with polycystic ovary syndrome. clinicaltrials.gov/ct2/show/NCT00005104(first posted April 2000). ">NCT00005104</a>; <a href="./references#CD013505-bbs2-0091" title="NCT00317928 . Efficacy of metformin in PCOS: metabolic and hormonal factors. clinicaltrials.gov/ct2/show/NCT00317928(first received April 2006). ">NCT00317928</a>; <a href="./references#CD013505-bbs2-0092" title="NCT00558077 . Second‐line treatments for anovulatory infertility in PCOS patients. clinicaltrials.gov/ct2/show/NCT00558077(first posted November 2007). ">NCT00558077</a>; <a href="./references#CD013505-bbs2-0093" title="NCT01679574 . Letrozole or combined clomiphene citrate metformin as a first line treatment in women with polycystic ovarian syndrome (PCO). clinicaltrials.gov/ct2/show/NCT01679574(first posted September 2012). ">NCT01679574</a>; <a href="./references#CD013505-bbs2-0094" title="NCT02562664 . Metformin improves clinical pregnancy rate in polycystic ovarian syndrome patients. clinicaltrials.gov/ct2/show/NCT02562664(first posted September 2015). ">NCT02562664</a>), and six are awaiting classification (<a href="./references#CD013505-bbs2-0084" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin–clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6(2):198‐201. ">Ayaz 2013a</a>; <a href="./references#CD013505-bbs2-0085" title="BeigiA . Randomized trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in polycystic ovary syndrome. Human Reproduction2006;21(i129):[Abstract]. ">Beigi 2006</a>; <a href="./references#CD013505-bbs2-0086" title="JahanS . Comparative study of efficacy among metformin, clomiphene citrate and aromatase inhibitor (letrozole) as the first‐line medication for ovulation induction, achievement of pregnancy and live birth in Asian women with polycystic ovarian syndrome: a prospective trial.. International Journal of Gynecology and Obstetrics2015;131(E503):[Abstract]. ">Jahan 2015</a>; <a href="./references#CD013505-bbs2-0087" title="RobinsonRD , SwezeyM , PropstA , BatesGW . Metformin added to clomiphene citrate does not improve pregnancy rates in hyperandrogenic, chronic anovulatory women: a randomized trial. Fertility and Sterility2003;80(3):S273‐S274, P‐464 [Abstract]. ">Robinson 2003</a>; <a href="./references#CD013505-bbs2-0088" title="SinghI , BedaiwyMA , HatwalA , KumarA , AgarwalA . Increased pregnancy rates with metformin and clomiphene citrate in non‐obese patients with polycystic ovary syndrome: prospective randomized study. Fertility and Sterility2001;76(3):Suppl 1, SP‐S94 [Abstract]. ">Singh 2001</a>; <a href="./references#CD013505-bbs2-0089" title="WilliamsCD , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92(3):S105 [Abstract]. ">Williams 2009</a>) (see <a href="#CD013505-fig-0001">Figure 1</a>). Of the 48 studies in the previous update, we have included 28 (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). We have included 13 additional studies in this review (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>), one of which the <a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a> review excluded (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>) and have 41 studies in total. </p> </section> <section id="CD013505-sec-0063"> <h4 class="title">Included studies</h4> <section id="CD013505-sec-0064"> <h5 class="title">Study design and setting</h5> <p>The newly included studies for this current update (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>), all recorded reproductive outcomes following treatment. </p> <p>Two compared metformin with placebo (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>). Seven compared metformin and CC with CC alone (<a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>). One compared metformin and LOD with LOD (<a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>). Three compared metformin with LOD (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>). One compared metformin and letrozole versus letrozole alone as well as metformin and CC versus CC alone (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), and one compared metformin versus CC as well as metformin and CC (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>). </p> <p>Twenty‐two of the included studies were documented as being double‐blind. Nine studies were not double‐blind (<a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), and the remainder were classified as unclear. </p> <p>One of the studies was a cross‐over trial (<a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>). We only analysed the first phase from <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> as we considered the washout period to be short (four weeks). </p> <p>The included studies originated from Australia, Bangladesh, Brazil, China, Denmark, Egypt, Finland, Hong Kong, India, Iran, Italy, Jordan, Malaysia, the Netherlands, Norway, New Zealand, Pakistan, South Africa, South Korea, Sweden, Tunisia, Turkey, UK, USA and Venezuela. </p> </section> <section id="CD013505-sec-0065"> <h5 class="title">Participants</h5> <p>The number of women in the studies ranged from 18 to 626, with 4552 participants in total. The range of BMI in included participants was 20.96 to 38.9 kg/m<sup>2</sup>. </p> <p>All the women had a diagnosis of PCOS based upon the Rotterdam Consensus criteria; two out of three of PCOS on ultrasound, oligo or anovulation, clinical or biochemical signs of hyperandrogenism (<a href="./references#CD013505-bbs2-0115" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). The age range of participants was 24.2 to 32.8 years with the range of fasting insulin concentrations between 6.3 and 54.7 mIU/L and testosterone levels of 1.5 to 11.4 nmol/L. However, several studies did not provide these data. </p> </section> <section id="CD013505-sec-0066"> <h5 class="title">Interventions</h5> <p>In total, all 41 trials assessed the benefits of using metformin for women with PCOS. Eighteen trials compared metformin alone with placebo or no treatment (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). </p> <p>Eighteen studies investigated the benefits of using metformin combined with CC on reproductive outcomes (<a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). Nine studies compared metformin versus CC (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> <p>One study compared metformin and letrozole to letrozole alone (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>). The same study also compared metformin and CC to CC. </p> <p>One study compared metformin and LOD with LOD alone (<a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>), and three studies compared metformin to LOD directly (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>). </p> <p>Eleven studies included specific advice on lifestyle modification in the study protocol (<a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> <p>The duration of the studies ranged from 4 to 96 weeks with an average of 19.7 weeks. The median daily dose of metformin used in the studies was 1500 mg. </p> </section> <section id="CD013505-sec-0067"> <h5 class="title">Outcomes</h5> <p>Most studies reported clinical pregnancy rate and ovulation rate but only 16 studies reported live birth rates (<a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). The four largest studies reporting live birth rate were <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a> and <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>. Nineteen studies reported gastrointestinal side effects (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). </p> </section> </section> <section id="CD013505-sec-0068"> <h4 class="title">Excluded studies</h4> <p>In this fourth update, we excluded a total of 42 studies. Of these, we excluded eight because the comparators were not relevant to the meta‐analysis (<a href="./references#CD013505-bbs2-0052" title="ElgaforIA . Efficacy of combined metformin‐letrozole in comparison with bilateral ovarian drilling in clomiphene‐resistant infertile women with polycystic ovarian syndrome. Archives of Gynecology and Obstetrics2013;288:119‐23. ">Elgafor 2013</a>; <a href="./references#CD013505-bbs2-0053" title="FayedMR , HamedT . Ovulation induction with rosiglitazone/clomiphene citrate versus metformin/clomiphene citrate in women with clomiphene citrate‐resistant polycystic ovary syndrome. Middle East Fertility Society Journal2009;14(4):257‐64. ">Fayed 2009</a>; <a href="./references#CD013505-bbs2-0055" title="HashimHA , ShokeirT , BadawyA . Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene‐resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2010;94(4):1405‐9. ">Hashim 2010</a>; <a href="./references#CD013505-bbs2-0056" title="HashumHA , LakanyNE , SheriefL . Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene‐resistant women with polycystic ovary syndrome: a randomized controlled trial. Journal of Obstetrics and Gynaecology Research2011;37(3):169‐77. ">Hashim 2011</a>; <a href="./references#CD013505-bbs2-0066" title="MelliMS , Kazemi‐ShishvaniM . The effectiveness of clomiphene citrate (CC) + metformin vs CC + metformin +fluoxetine in PCOS CC‐resistant patients [P‐447]. Human Reproduction2010;25 Suppl 1(6):[Abstract]. ">Melli 2010</a>; <a href="./references#CD013505-bbs2-0074" title="RezkM , ShaheenA , El‐NasrIS . Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene‐resistant polycystic ovary syndrome: a randomized clinical trial. Gynecological Endocrinology2018;34(4):298‐300. ">Rezk 2018</a>; <a href="./references#CD013505-bbs2-0079" title="SohrabvandF , AnsariSh , BagheriM . Efficacy of combined metformin–letrozole in comparison with metformin–clomiphene citrate in clomiphene‐resistant infertile women with polycystic ovarian disease. Human Reproduction2006;21(6):1432‐5. ">Sohrabvand 2006</a>; <a href="./references#CD013505-bbs2-0081" title="WeerakietS , SophonsritsukA , LertvikoolS , SatirapotC , LeelaphiwatS , JultanmasR . Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research2011;37(9):1229‐37. ">Weerakiet 2011</a>), seven because there were no reproductive outcomes reported (<a href="./references#CD013505-bbs2-0043" title="AshrafiniaM , HosseiniR , MoiniA , EslamiB , AsgariZ . Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2009;107:236‐9. ">Ashrafinia 2009</a>; <a href="./references#CD013505-bbs2-0044" title="AbuchonM , LiemanH , SteinD , CohenHW , IsaacB , AdelG , et al. Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). Reproductive Sciences2009;16(10):938‐46. ">Aubuchon 2009</a>; <a href="./references#CD013505-bbs2-0050" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD013505-bbs2-0051" title="EisenhardtS , SchwarzmannN , HenschelV , GermeyerA , vonWolffM , HamannA , et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(3):946‐52. ">Eisenhardt 2006</a>; <a href="./references#CD013505-bbs2-0063" title="MacielGA , Soares JuniorJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC . Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81(2):355‐60. ">Maciel 2004</a>; <a href="./references#CD013505-bbs2-0067" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomised, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD013505-bbs2-0080" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. ">Trolle 2007</a>), four because they were review articles (<a href="./references#CD013505-bbs2-0065" title="MayhewMS . Treatment for polycystic ovary syndrome. Journal for Nurse Practitioners2011;7(6):517‐18. ">Mayhew 2011</a>; <a href="./references#CD013505-bbs2-0070" title="PalombaS , Orio JrF , NardoLG , FalboA , RussoT , CoreaD , et al. Live birth rate was higher with metformin treatment than after laparoscopic ovarian diathermy in women with PCOS. Reproductive Endocrinology and Infertility2005;7:145‐6. ">Palomba 2005c</a>; <a href="./references#CD013505-bbs2-0072" title="PinnowS , KrausC . What is the most effective treatment for polycystic ovary syndrome for patients who cannot tolerate metformin?. Evidence‐based PracticeSeptember 2008;11:7‐8. ">Pinnow 2008</a>; <a href="./references#CD013505-bbs2-0082" title="WisniewskiM , PetersonM . Is metformin beneficial for the treatment of infertility in women with PCOS?. JAAPA2009;22(4):49‐50. ">Wisniewski 2009</a>), four because they were not RCTs (<a href="./references#CD013505-bbs2-0060" title="KocakM , CaliskanE , SimsirC , HaberalA . Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate‐resistant women with polycystic ovary syndrome. Fertility and Sterility2002;77(1):101‐6. ">Kocak 2002</a>; <a href="./references#CD013505-bbs2-0068" title="NeveuN , GrangerL , St‐MichelP , LavoieHB . Comparison of clomiphene citrate metformin, or the combination of both for first‐line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertility and Sterility2007;87(1):113‐20. ">Neveu 2007</a>; <a href="./references#CD013505-bbs2-0069" title="PalombaS , Orio JrF , FalboA , RussoT , CaterinaG , MangusoF , et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo‐anovulatory CC‐resistant women wtih polycystic ovary syndrome. Clinical Endocrinology2005;63:631‐5. ">Palomba 2005b</a>; <a href="./references#CD013505-bbs2-0071" title="PalombaS , Orio JrF , FalboA , RussoT , TolinoA , ZulloF . Clomiphene citrate versus metformin as first‐line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2007;92(9):3498‐503. ">Palomba 2007</a>), two because they were quasi‐RCTs (<a href="./references#CD013505-bbs2-0048" title="BonakdaranS , KhorasaniZM , DavachiB , KhorasaniM . The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo‐controlled clinical trial. Iran Journal of Reproductive Medicine2012;10(5):465‐72. ">Bonakdaran 2012</a>; <a href="./references#CD013505-bbs2-0049" title="ChaudhuryK , ChaudhuryS , ChowdhuryS . Does metformin augment the ovulation inducing effects of clomiphene in non‐obese women with polycystic ovary syndrome?. Journal of Indian Medicine Association2008;106(10):643‐8. ">Chaudhury 2008</a>), three because the participants underwent IVF or intrauterine insemination (<a href="./references#CD013505-bbs2-0062" title="LeanzaV , CocoL , GrassoF , LeanzaG , ZarboG , PalumboM . Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome. Minerva Ginecologica2014;66(3):299‐301. ">Leanza 2014</a>; <a href="./references#CD013505-bbs2-0078" title="SavicB , MilacicD , ZarkovicA . Insulin sensitising agents in PCOS treatment. International Journal of Obstetrics &amp; Gynecology2003;83(Suppl 3):[Abstract]. ">Savic 2003</a>; <a href="./references#CD013505-bbs2-0075" title="RonsiniS , DiFilippoMA , GriecoN , CappeilloF , D'AnielloG . Ovulation induction in insulin‐resistant infertility. Human Reproduction2006;21(Suppl):[Abstract]. ">Ronsini 2006</a>), 12 because they used human chorionic gonadotropin (hCG) or human menopausal gonadotropin in addition to ovulation agents to trigger ovulation (<a href="./references#CD013505-bbs2-0042" title="AbuelgharWM , ElkadyOS , KhameesAA . Clomiphene citrate alone, in combination with metformin or in combination with pioglitazone as first line therapy in induction of ovulation in infertile women with polycystic ovary syndrome, a randomised controlled trial. Middle East Fertility Society Journal2013;18:135‐41. ">Abuelghar 2013</a>; <a href="./references#CD013505-bbs2-0045" title="AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs clomiphene citrate alone: Polycystic ovarian syndrome. Journal of Human Reproductive SciencesJanuary‐March 2013;6(1):15‐18. ">Ayaz 2013b</a>; <a href="./references#CD013505-bbs2-0046" title="AygenEM , GuzelZ , OzgunT , AtakulT , SahinY . The use of letrozole for ovulation induction in infertile women with polycystic ovarian syndrome. Erciyes Medical Journal2007;29(3):195‐200. ">Aygen 2007</a>; <a href="./references#CD013505-bbs2-0054" title="GadaNJ , PurandareCN , LopezJA , SalunkheR . Role of metformin in PCOD: a comparative study. XVI FIGO World Congress of O &amp; G, 2000 Sep 3‐8; Washington DC. 2000; Vol. 2:107‐9. ">Gada 2000</a>; <a href="./references#CD013505-bbs2-0057" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD013505-bbs2-0058" title="KaticaV , RamaA , AbadzicN . Efficacy of ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome ‐ pilot study. Folia Medica2014;49(1):37‐42. ">Katica 2014</a>; <a href="./references#CD013505-bbs2-0059" title="KazerooniT , GhaffarpasandF , KazerooniY , KazerooniM , SetoodehS . Short‐term metformin treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2009;107(1):50‐3. ">Kazerooni 2009</a>; <a href="./references#CD013505-bbs2-0064" title="MagedAM , ElsawahH , AbdelhafezA , BakryA , Al MostafaW . The adjuvant effect of metformin and N‐acetylcysteine to clomiphene citrate in induction of ovulation in patients with polycystic ovary syndrome. Gynecological Endocrinology2015;31(8):635‐8. ">Maged 2015</a>; <a href="./references#CD013505-bbs2-0073" title="RamzyA , El‐KatebS , Al‐InanyH , AboulmaatyZ , BadieM . The use of metformin in overweight and lean infertile patients with polycystic ovarian syndrome: a randomised controlled trial. Middle East Fertility Society Journal2003;8:143‐9. ">Ramzy 2003</a>; <a href="./references#CD013505-bbs2-0076" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics and Gynecology and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>; <a href="./references#CD013505-bbs2-0077" title="SantonocitoV , RapisardaV , AbruzzoSR , PollicinoR , CocoL , ZarboG . Comparison between clomiphene citrate and metformin for induction of ovulatory cycles in infertile nonobese women with polycystic ovary syndrome. Giornale Italiano di Ostetricia e Ginecologia2009;31(11‐12):455‐60. ">Santonocito 2009</a>; <a href="./references#CD013505-bbs2-0083" title="XiaolinC , JiweiG , JingX . Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome. Chinese Journal of EpidemiologyDecember 2014;35(12):1389‐91. ">Xiaolin 2014</a>), one because the diagnosis of PCOS was made on ultrasound findings alone (<a href="./references#CD013505-bbs2-0061" title="KoreSJ , LakhotiaS , ParikhM , AmbiyeVR . Polycystic ovarian disease: impact of metformin therapy. Bombay Hospital Journal2007;49(2):1‐6. ">Kore 2007</a>), and one because we could not find the original abstract (<a href="./references#CD013505-bbs2-0047" title="BillaN , KapollaN , NicopoulouS , KoukkouE , VenakiE , AdamopoulosDA , et al. Effects of metformin on reproductive axis and metabolism in women with polycystic ovary syndrome (abstract). European Journal of Clinical Investigation2005;35(Suppl 2). ">Billa 2005</a>). </p> <p>A summary of studies included and excluded in this review can be found in <a href="#CD013505-fig-0001">Figure 1</a>. </p> </section> </section> <section id="CD013505-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD013505-fig-0002">Figure 2</a> and <a href="#CD013505-fig-0003">Figure 3</a> for a summary of the risk of bias. </p> <p>We performed sensitivity analysis by including data only from studies with low risk of bias, as determined by sequence generation, allocation concealment and blinding methodology. Only 12 out of 41 studies met this criterion (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). Two out of the 13 newly included studies met this criterion (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>). </p> <section id="CD013505-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD013505-sec-0071"> <h5 class="title">Sequence generation</h5> <p>Sequence generation was unclear in 18 studies (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). Two studies were high risk: <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a> included consecutive non‐probability sampling in their methods of randomisation; and in <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>, participants' choice of pink or green bottle represented a sealed, opaque envelope. The remaining studies were low risk (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>), where they all used computer‐generated randomisation methods. </p> </section> <section id="CD013505-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was high risk in two studies: <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a> used consecutive sampling; and <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> used clearly labelled cards picked out of a box. Allocation concealment was low risk in 14 studies (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). Allocation concealment was unclear in 25 studies (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). </p> </section> </section> <section id="CD013505-sec-0073"> <h4 class="title">Blinding</h4> <p>Performance bias was high risk in four studies (<a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), all of which did not blind participants. <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a> compared LOD to metformin, therefore blinding was not feasible when comparing surgery to medications. We judged 20 studies at low risk of performance bias (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>), where participants were blinded to the treatment, and we determined that 17 studies, where information was inadequate, were at unclear risk (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). </p> <p>Detection bias was high risk in six studies (<a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), where the investigators were not blinded to the treatment comparators; and low risk in 17 studies (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>), where participants were blinded to the treatment. We judged 18 studies at unclear risk, where information was inadequate (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). </p> </section> <section id="CD013505-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Eighteen studies were at high risk of attrition bias due to high dropout rates, unequal dropouts between the groups, not providing missing data, not using intention‐to‐treat analysis or use of per‐protocol analysis (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>. Eighteen studies were at low risk of attrition bias (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). We classified the remaining studies as unclear risk because of insufficient information (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>). </p> </section> <section id="CD013505-sec-0075"> <h4 class="title">Selective reporting</h4> <p>We judged 16 studies to be at low risk of selective reporting (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0006" title="FatimaA , KhanSA , SaifuddinZ , AslamR . Comparison of efficacy of clomiphene citrate alone and with metformin for treatment of infertility in polycystic ovarian syndrome. Rawal Medical Journal2018;43(2):285‐8. ">Fatima 2018</a>; <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>), because they clearly reported all stated outcomes. One study (<a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>), did not report on all outcomes including endocrine and lipid profiles and we classified it as high risk. The remaining studies had insufficient information and we classified them as unclear risk (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> <p>Multi‐arm studies have an increased risk of reporting bias. There were five 3‐armed studies (<a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), and two 4‐armed studies (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), however, all studies clearly reported baseline characteristics and outcome data for each arm separately. </p> </section> <section id="CD013505-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies appeared to be at high risk of other sources of bias: <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a> was not published, therefore had not undergone the peer review process; and <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> underwent an ad hoc change in sample size. We classified four studies as unclear risk. <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> reported a discrepant treatment period between groups. <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a> may have duplicated some participants from a previous study with a crossover of recruitment periods, and there was no reply from the study author to clarify. <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> included participants who were anovulatory however, some of these participants did ovulate with no treatment. <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a> did not provide baseline characteristics between groups and hence there may be confounding factors present that affect the results. The majority of the studies were low risk with no evidence of other bias. </p> </section> </section> <section id="CD013505-sec-0077"> <h3 class="title" id="CD013505-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD013505-tbl-0001"><b>Summary of findings for the main comparison</b> Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</a>; <a href="./full#CD013505-tbl-0002"><b>Summary of findings 2</b> Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</a>; <a href="./full#CD013505-tbl-0003"><b>Summary of findings 3</b> Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</a> </p> <p>We have presented forest plots for the primary outcome live birth rate in <a href="#CD013505-fig-0004">Figure 4</a>; <a href="#CD013505-fig-0005">Figure 5</a>; <a href="#CD013505-fig-0006">Figure 6</a>, for <a href="./references#CD013505-fig-0008" title="">Analysis 1.1</a>, <a href="./references#CD013505-fig-0021" title="">Analysis 2.1</a> and <a href="./references#CD013505-fig-0034" title="">Analysis 3.1</a>, respectively. </p> <div class="figure" id="CD013505-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1. Metformin versus placebo or no treatment, outcome 1.1, live birth rate" data-id="CD013505-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1. Metformin versus placebo or no treatment, outcome 1.1, live birth rate </p> </div> </div> </div> <div class="figure" id="CD013505-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2. Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1, live birth rate" data-id="CD013505-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2. Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1, live birth rate </p> </div> </div> </div> <div class="figure" id="CD013505-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 3. Metformin versus clomiphene citrate, outcome 3.1, live birth rate" data-id="CD013505-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 3. Metformin versus clomiphene citrate, outcome 3.1, live birth rate </p> </div> </div> </div> <section id="CD013505-sec-0078"> <h4 class="title">1. Metformin versus placebo or no treatment</h4> <section id="CD013505-sec-0079"> <h5 class="title">1.1 Live birth rate</h5> <p>When we compared metformin to placebo, only a limited number of studies reported live birth rate (<a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). Pooled evidence from these four studies showed that live birth rate may improve slightly with metformin, with a number needed to treat for an additional beneficial outcome of 13 women (OR 1.59, 95% CI 1.01 to 2.50; I<sup>2</sup> = 0%; 4 studies, 435 women; low‐quality evidence; <a href="./references#CD013505-fig-0008" title="">Analysis 1.1</a>). This suggests that for a live birth rate of 19% following placebo, the live birth rate following metformin would be between 19% and 37%. However, the wide‐ranging confidence intervals and low quality of the evidence make the advantage offered by metformin difficult to interpret clinically. </p> <p>In the subgroup analysis by obesity status the test for differences showed no difference between obese and non‐obese women. There was no clear evidence of a difference in live birth rate in either subgroup (BMI of &lt; 30 kg/m<sup>2</sup>: OR 1.51, 95% CI 0.94 to 2.44; I<sup>2</sup> = 0%; 3 studies, 370 women; or BMI &gt; 30 kg/ m<sup>2</sup>: OR 2.87, 95% CI 0.51 to 16.01; 1 study, 65 women). However, the broad confidence intervals due to reducing the number of combined studies for this analysis, render the results unclear. A sensitivity analysis, which excluded studies with unclear or high risk of bias left two studies remaining (OR 1.64, 95% CI 1.02 to 2.63; I<sup>2</sup> = 0%; 2 studies, 385 women; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). The large and high‐quality study by <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a> contributed 93.8% of the weight of the result (OR 0.95, 95% CI 0.95 to 2.55; 320 women). These results therefore suggest a potential benefit in live birth rate when using metformin compared with placebo, although the number of studies were small. </p> </section> <section id="CD013505-sec-0080"> <h5 class="title">1.2 Adverse events (gastrointestinal side effects)</h5> <p>Women in the metformin group experienced a higher incidence of gastrointestinal side effects than the placebo group (OR 4.00, 95% CI 2.63 to 6.09; I<sup>2</sup> = 39%; 7 studies, 713 women; moderate‐quality evidence; <a href="./references#CD013505-fig-0009" title="">Analysis 1.2</a>). This suggests that with placebo, the risk of adverse effects is 10% whereas with metformin the risk of adverse gastrointestinal side effects increases to between 22% and 40%. Despite the large confidence interval, the heterogeneity is moderate, which provides evidence that women are more likely to experience gastrointestinal side effects. The heterogeneity and wide confidence intervals could be explained by the subjective nature of gastrointestinal side effects and reliance on participant self‐reporting. Sensitivity analysis, which excluded studies with unclear or high risk of bias did not change the inference. In the subgroup analysis by BMI, the test for differences showed no evidence of a difference between obese and non‐obese women. </p> </section> <section id="CD013505-sec-0081"> <h5 class="title">1.3 Clinical pregnancy rate</h5> <p>Eleven trials reported clinical pregnancy rates (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a>). Metformin probably improves pregnancy rates compared with placebo (OR 1.98, 95% CI 1.47 to 2.65; I<sup>2</sup> = 30%; 11 studies, 1213 women; moderate‐quality evidence; <a href="./references#CD013505-fig-0010" title="">Analysis 1.3</a>). This suggests that the clinical pregnancy rate with placebo is 15%, which may increase to a range from 21% to 32% with metformin. In subgroup analysis by BMI the test for differences showed no evidence of a difference between obese and non‐obese women. In an attempt to improve heterogeneity we performed a sensitivity analysis, which excluded studies with unclear or high risk of bias, including the following studies: <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0013" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>. However, this did not alter the inference or heterogeneity significantly. </p> </section> <section id="CD013505-sec-0082"> <h5 class="title">1.4 Ovulation rate</h5> <p>There was evidence that metformin may improve ovulation rate per woman (OR 2.64, 95% CI 1.85 to 3.75; I<sup>2</sup> = 61%; 13 studies, 684 women; low‐quality evidence; <a href="./references#CD013505-fig-0011" title="">Analysis 1.4</a>). This suggests that the ovulation rate with placebo is 24%, which may increase to a range from 37% to 54% with metformin. We have presented ovulation rate per cycle in <a href="#CD013505-tbl-0006">Table 3</a>. Subgroup analysis by obesity status suggested no significant difference between women with a BMI of 30 kg/m<sup>2</sup> or higher compared with women with a BMI of under 30 kg/m<sup>2</sup> (test for subgroup differences: Chi² = 3.79, df = 1 (P = 0.05), I² = 73.6%. When we pooled both subgroups, heterogeneity was improved, after which included only five studies (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), with an overall I<sup>2</sup> statistic value of 76% . However, the overall inference remained unchanged. </p> </section> <section id="CD013505-sec-0083"> <h5 class="title">1.5 Miscarriage and 1.6 Miscarriage per pregnancy</h5> <p>There is no evidence that metformin compared with placebo increases miscarriage rate per woman (OR 1.08, 95% CI 0.50 to 2.35; I<sup>2</sup> = 0%; 4 studies, 748 women; low‐quality evidence; <a href="./references#CD013505-fig-0012" title="">Analysis 1.5</a>). This suggests that a miscarriage rate of 4% with placebo may change to between 2% and 9% with metformin. A sensitivity analysis using per pregnancy rates was also inconclusive (OR 0.58, 95% CI 0.25 to 1.34; I<sup>2</sup> = 0%; 4 studies, 200 pregnancies; low‐quality evidence; <a href="./references#CD013505-fig-0013" title="">Analysis 1.6</a>). A subgroup analysis by obesity status showed no evidence of a difference between the obese and non‐obese women. However, only one study was available with women with BMI more than 30 kg/m<sup>2</sup> (<a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). </p> </section> <section id="CD013505-sec-0084"> <h5 class="title">1.7 Multiple pregnancy and 1.8 Multiple pregnancy per pregnancy</h5> <p>Only one study reported multiple pregnancy rates (<a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). We are uncertain of the effect of metformin compared with placebo on multiple pregnancy rates per woman (OR 0.33, 95% CI 0.01 to 8.49; 1 study, 65 women; <a href="./references#CD013505-fig-0014" title="">Analysis 1.7</a>). All women in this group were obese with BMI more than 32 kg/m<sup>2</sup>. A sensitivity analysis using per pregnancy rates was also inconclusive (OR 0.20, 95% CI 0.01 to 6.04; 1 study, 12 pregnancies; <a href="./references#CD013505-fig-0015" title="">Analysis 1.8</a>). </p> </section> <section id="CD013505-sec-0085"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0086"> <h6 class="title">1.9 Body mass index</h6> <p>There is no evidence that metformin compared with placebo lowers BMI (MD −0.04, 95% CI −0.29 to 0.21; I<sup>2</sup> = 0%; 10 studies, 589 women; <a href="./references#CD013505-fig-0016" title="">Analysis 1.9</a>) with an average duration of treatment of six months and average dose of 1500 mg. <a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> provided 79% of the weight of this analysis, which found no significant evidence of a difference in BMI (MD 0.00, 95% CI −0.28 to 0.28). The overall heterogeneity was low (I<sup>2</sup> = 0%). Sensitivity analysis by study quality did not change the inference (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). </p> </section> </section> <section id="CD013505-sec-0087"> <h5 class="title">Endocrine outcomes</h5> <section id="CD013505-sec-0088"> <h6 class="title">1.10 Serum testosterone</h6> <p>Evidence showed that metformin may reduce serum total testosterone levels with a MD of −0.41 nmol/L (95% CI −0.48 to −0.35; 11 studies, 707 women; <a href="./references#CD013505-fig-0017" title="">Analysis 1.10</a>). However, we observed high heterogeneity (I<sup>2</sup> = 95%). In subgroup analysis by BMI, there was no evidence of a difference between obese and non‐obese women (test for subgroup differences: Chi² = 2.71, df = 1 (P = 0.10), I<sup>2</sup> = 63.1%). Furthermore, different biochemical assays used in different studies could contribute to the heterogeneity. Sensitivity analysis by study quality did not improve the heterogeneity (I<sup>2</sup> = 97%). However, removing the two extreme results (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>), improved heterogeneity (non‐obese group I<sup>2</sup> = 0%; obese group I<sup>2</sup> = 57%) without altering the inference. (MD ‐0.41, 95% CI ‐0.48 to ‐0.35; participants = 707; studies = 12; I<sup>2</sup> = 95%) </p> </section> <section id="CD013505-sec-0089"> <h6 class="title">1.11 Serum sex hormone‐binding globulin</h6> <p>We are uncertain of the effect of metformin for serum sex hormone‐binding globulin levels (MD −1.70, 95% CI −4.77 to 1.36; I<sup>2</sup> = 70%; 10 studies, 649 women; <a href="./references#CD013505-fig-0018" title="">Analysis 1.11</a>). Neither the subgroup analysis nor the sensitivity analysis by study quality changed the inference, yet removal of the studies with high or unclear risk of bias (<a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>), did improve the heterogeneity (I<sup>2</sup> = 6%). </p> </section> </section> <section id="CD013505-sec-0090"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0091"> <h6 class="title">1.12 Fasting glucose</h6> <p>Metformin may reduce the fasting glucose levels compared with placebo (MD 0.01, 95% CI −0.04 to 0.06; I<sup>2</sup> = 65%; 10 studies, 677 women; <a href="./references#CD013505-fig-0019" title="">Analysis 1.12</a>). Subgroup analysis only improved heterogeneity in the obese group (I<sup>2</sup> = 49%) without changing the inference. Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>), improved overall heterogeneity (I<sup>2</sup> = 20%) and the results indicated a minimal effect of metformin on fasting glucose concentrations (MD −0.09 mmol/L, 95% CI −0.17 to 0.00). </p> </section> <section id="CD013505-sec-0092"> <h6 class="title">1.13 Fasting insulin</h6> <p>We are uncertain of an effect of metformin compared with placebo on fasting insulin levels with a MD −1.84 (95% CI −4.27 to 0.59; 8 studies, 361 women; <a href="./references#CD013505-fig-0020" title="">Analysis 1.13</a>) but with significant heterogeneity (I<sup>2</sup> = 67%). In subgroup analysis by BMI the test for subgroup differences showed no evidence of a difference between obese and non‐obese women (test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.97), I<sup>2</sup> = 0%). Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>), did not alter the inferences. </p> </section> </section> </section> <section id="CD013505-sec-0093"> <h4 class="title">2. Metformin and CC versus CC alone</h4> <section id="CD013505-sec-0094"> <h5 class="title">2.1 Live birth rate</h5> <p>We are uncertain of an effect of metformin and CC on live birth rates compared with CC alone (OR 1.27, 95% CI 0.98 to 1.65; I<sup>2</sup> = 28%; 10 studies, 1219 women; low‐quality evidence; <a href="./references#CD013505-fig-0021" title="">Analysis 2.1</a>). The live birth rate with CC alone is 24%, which may change to between 23% to 34% with combined therapy. </p> <p>In subgroup analysis, the test for subgroup differences showed no evidence of a difference between obese women (OR 1.41, 95% CI 0.95 to 2.09; 4 studies, 554 women) and non‐obese women (OR 1.18, 95% CI 0.84 to 1.67; 6 studies, 665 women) with a P value of 0.52. Sensitivity analysis by evidence quality (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), with 843 women, also did not change the inference nor improve heterogeneity. </p> </section> <section id="CD013505-sec-0095"> <h5 class="title">2.2 Adverse events</h5> <p>Metformin and CC probably increases the frequency of gastrointestinal side effects, including nausea and vomiting, compared with CC alone (OR 4.26, 95% CI 2.83 to 6.40; I<sup>2</sup> = 8%; 6 studies, 852 women; moderate‐quality evidence; <a href="./references#CD013505-fig-0022" title="">Analysis 2.2</a>). With CC alone, the risk of gastrointestinal side effects is 9%, which increases to between 21% to 37% with combined therapy. The confidence interval is large, however, the heterogeneity is low and therefore suggests that women are probably more likely to experience gastrointestinal side effects compared with CC alone. Only one study included obese women (OR 2.36, 95% CI 0.19 to 29.71; 27 women; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>), and one study did not record BMI (OR 14.75, 95% CI 0.81 to 269.34; 100 women; <a href="./references#CD013505-bbs2-0034" title="RajaA , HashmiSN , SultanaN , RashidH . Presentation of polycystic ovary syndrome and its management with clomiphene alone and in combination with metformin. Journal of Ayub Medical College, Abbottabad2005;17(2):50‐3. ">Raja 2005</a>). Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), did not change our findings. </p> </section> <section id="CD013505-sec-0096"> <h5 class="title">2.3 Clinical pregnancy rate</h5> <p>Metformin and CC probably improves pregnancy rate compared with CC alone (OR 1.62, 95% CI 1.32 to 1.99; I<sup>2</sup> = 31%; 19 studies, 1790 women; moderate‐quality evidence; <a href="./references#CD013505-fig-0023" title="">Analysis 2.3</a>). This suggests that the clinical pregnancy rate with CC alone is 28% which may increase to between 34% and 43% with combination therapy. </p> <p>In subgroup analysis, the test for subgroup differences showed no evidence of a difference between the subgroups: the effect on pregnancy rates was seen in both analyses: obese group (OR 1.74, 95% CI 1.24 to 2.43; 8 studies, 666 women) and non‐obese group (OR 1.40, 95% CI 1.06 to 1.86; 9 studies, 896 women). Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), with 843 participants, did improve heterogeneity (I<sup>2</sup> = 3%) but also altered the inference (OR 1.29, 95% CI 0.98 to 1.70). </p> </section> <section id="CD013505-sec-0097"> <h5 class="title">2.4 Ovulation rate and 2.5 Ovulation rate by CC sensitivity and resistance</h5> <p>Metformin and CC may improve ovulation per woman compared with CC alone, (OR 1.65, 95% CI 1.35 to 2.03; I<sup>2</sup> = 63%; 21 studies, 1568 women; low‐quality evidence; <a href="./references#CD013505-fig-0024" title="">Analysis 2.4</a>). This suggests that the ovulation rate with CC alone is 50% which may increase to between 58% and 68% with combination therapy. We have presented ovulation rate per cycle in <a href="#CD013505-tbl-0007">Table 4</a>. In subgroup analysis, the test for subgroup differences showed no evidence of a difference between obese and non‐obese women (P = 0.16). Heterogenity remained high (I<sup>2</sup> = 70%) in the obese subgroup, but the direction of effect was consistent. </p> <p>Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), did improve heterogeneity (I<sup>2</sup> = 7%) however, it reduced the inference (OR 0.98, 95% CI 0.73 to 1.32; 5 studies, 777 women). </p> <p>We conducted a subgroup analysis based on sensitivity to CC. Seven studies recorded CC‐resistance status. Six of these included women with CC resistance (<a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>). This analysis showed an improvement in ovulation rate with combined therapy (OR 4.97, 95% CI 2.46 to 10.03; I<sup>2</sup> = 0%; 6 studies, 156 women; moderate‐quality evidence; <a href="./references#CD013505-fig-0025" title="">Analysis 2.5</a>). Only one small study of CC‐sensitive women was available, and we are unable to draw a conclusion from the result (OR 3.55, 95% CI 0.65 to 19.37; 56 women; <a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>). </p> </section> <section id="CD013505-sec-0098"> <h5 class="title">2.6 Miscarriage rate and 2.7 Miscarriage rate per pregnancy</h5> <p>When we pooled data from 10 studies, we found no effect of metformin and CC compared with CC alone on miscarriage (OR 1.35, 95% CI 0.91 to 2.00; I<sup>2</sup> = 0%; 10 studies, 1206 women;low‐quality evidence; <a href="./references#CD013505-fig-0026" title="">Analysis 2.6</a>). This suggests that the miscarriage rate with CC alone is 8%, which may change to between 7% and 14% with combination therapy. When we analysed a subgroup by BMI, the test for subgroup differences showed no evidence of a difference between obese and non‐obese women (P = 0.72). </p> <p>When we performed an analysis of miscarriage rate per pregnancy, there was no clear evidence of a difference between the groups (OR 1.07, 95% CI 0.69 to 1.66; I<sup>2</sup> = 0%; 10 studies, 471 pregnancies; <a href="./references#CD013505-fig-0027" title="">Analysis 2.7</a>), with no evidence of a difference between the BMI subgroups (P = 0.91). Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), also did not alter the inference. Any increase in miscarriage conferred by using CC therapy in isolation is therefore difficult to interpret and apply clinically. </p> <p>One study reported ectopic pregnancy rate (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>). There was one ectopic pregnancy in the metformin and CC group and one ectopic pregnancy in the CC‐alone group. </p> </section> <section id="CD013505-sec-0099"> <h5 class="title">2.8 Multiple pregnancy rate and 2.9 Multiple pregnancy rate per pregnancy</h5> <p>We are uncertain of an effect of metformin and CC versus CC alone for multiple pregnancy rate (OR 0.56, 95% CI 0.18 to 1.68; I<sup>2</sup> = 0%; 6 studies, 1003 women; <a href="./references#CD013505-fig-0028" title="">Analysis 2.8</a>). There was no evidence of a difference between BMI subgroups (P = 0.81). Sensitivity analysis using per pregnancy rates did not produce different findings (OR 0.46, 95% CI 0.15 to 1.42; I<sup>2</sup> = 0%; 6 studies, 342 pregnancies; <a href="./references#CD013505-fig-0029" title="">Analysis 2.9</a>). Sensitivity analysis by study quality (<a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), did not alter the inference either. </p> </section> <section id="CD013505-sec-0100"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0101"> <h6 class="title">2.10 Body mass index</h6> <p>Metformin and CC probably reduce BMI compared with CC alone (MD −4.44, 95% CI −6.11 to −2.77; I<sup>2</sup> = 0%; 3 studies, 105 women; <a href="./references#CD013505-fig-0030" title="">Analysis 2.10</a>), however, the number of participants is small. Only one study had non‐obese women (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>), however, there was no difference seen between subgroups of BMI (P = 0.50). </p> </section> </section> <section id="CD013505-sec-0102"> <h5 class="title">Endocrine outcomes</h5> <section id="CD013505-sec-0103"> <h6 class="title">2.11 Serum testosterone</h6> <p>We are uncertain of the effect of metformin and CC on reducing testosterone levels in women compared with CC alone (MD −0.37, 95% CI −0.60 to −0.13; I<sup>2</sup> = 0%; 3 studies, 105 women; <a href="./references#CD013505-fig-0031" title="">Analysis 2.11</a>). There was no evidence of a difference between BMI subgroups (P = 0.80) however, there were only two studies with obese women (<a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a>; <a href="./references#CD013505-bbs2-0035" title="RefaieAM , IbrahimGA , Al OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Journal2005;10(2):142‐9. ">Refaie 2005</a>), and one study with non‐obese women (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>). </p> </section> <section id="CD013505-sec-0104"> <h6 class="title">Serum sex hormone‐binding globulin</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0105"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0106"> <h6 class="title">2.12 Fasting glucose</h6> <p>We are uncertain of the effect of metformin and CC on reducing fasting glucose levels in women compared with CC alone (MD −0.21, 95% CI −0.29 to −0.12; I<sup>2</sup> = 0%; 2 studies, 71 women; <a href="./references#CD013505-fig-0032" title="">Analysis 2.12</a>). There was no evidence of a difference between BMI subgroups (P = 0.58) however, there was only one study with obese women and one study with non‐obese women (<a href="./references#CD013505-bbs2-0017" title="KoSH , LeeSH . The effect of metformin therapy on clomiphene citrate‐resistant polycystic ovarian syndrome women. Korean Journal of Fertility and Sterility2001;28(4):255‐64. ">Ko 2001</a> and <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a> respectively). </p> </section> <section id="CD013505-sec-0107"> <h6 class="title">2.13 Fasting insulin</h6> <p>Metformin and CC may reduce insulin levels compared with CC alone (MD −6.57, 95% CI −7.84 to −5.29; I<sup>2</sup> = 99%; 3 studies, 105 women; <a href="./references#CD013505-fig-0033" title="">Analysis 2.13</a>). Subgroup analysis of BMI suggested that non‐obese women responded better to combined metformin and CC alone (MD −15.20, 95% CI −18.33 to −12.07; 50 women) compared with obese women (MD −4.86, 95% CI −6.26 to −3.47; 55 women) however, there was only one study that included non‐obese women (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>). </p> </section> </section> </section> <section id="CD013505-sec-0108"> <h4 class="title">3. Metformin versus CC</h4> <section id="CD013505-sec-0109"> <h5 class="title">3.1 Live birth rate</h5> <p>When we combined the data from five studies (<a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), we were uncertain of an effect of metformin compared with CC on live birth rate, with high heterogeneity (OR 0.70, 95% CI 0.48 to 1.01; I<sup>2</sup> = 86%; 5 studies, 741 women; very low‐quality evidence; <a href="./references#CD013505-fig-0034" title="">Analysis 3.1</a>). However, in the subgroup analysis by obesity status, there was evidence of a difference between the obese and non‐obese women (test for subgroup differences: Chi<sup>2</sup> = 19.41, df = 1, P &lt; 0.0001, I<sup>2</sup> = 94.8%). Among obese women, live birth rate was lower in the metformin group (OR 0.30, 95% CI 0.17 to 0.52; 2 studies, 500 women); 62% of the weight of this finding was provided by a single study (<a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>). In the non‐obese subgroup the direction of effect favoured metformin with high heterogeneity (OR 1.71, 95% CI 1.00 to 2.94; I<sup>2</sup> = 78%; 3 studies, 241 women; very low‐quality evidence). This suggests that the live birth rate of non‐obese women with CC is 26%, which may increase to between 26% and 50% with metformin, whereas the live birth rate of obese women is 22%, which may decrease to between 5% to 13% with metformin. </p> </section> <section id="CD013505-sec-0110"> <h5 class="title">Adverse events (gastrointestinal side effects)</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0111"> <h5 class="title">3.2 Clinical pregnancy rate</h5> <p>The overall heterogeneity was high (I<sup>2</sup> = 77%) and the data were not appropriate for pooling because the results were too discrepant between non‐obese and obese women. Subgroup analysis by obesity status showed evidence of a difference between the subgroups (test for subgroup differences: Chi² = 23.30, df = 1 (P &lt; 0.00001, I<sup>2</sup> = 95.7%; <a href="./references#CD013505-fig-0035" title="">Analysis 3.2</a>). In the obese group, higher pregnancy rates were seen amongst women taking CC compared with metformin (OR 0.34, 95% CI 0.21 to 0.55; I<sup>2</sup> = 0%; 2 studies, 500 women; low‐quality evidence) whereas in the non‐obese group, metformin favoured higher pregnancy rates (OR 1.56, 95% CI 1.06 to 2.29; I<sup>2</sup> = 26%; 6 studies, 530 women; low‐quality evidence). This suggests that the clinical pregnancy rate of non‐obese women with CC is 26%, which may increase to between 27% and 44% with metformin, whereas the clinical pregnancy rate of obese women is 28%, which may decrease to between 7% to 17% with metformin. Sensitivity analysis by study quality did not change the heterogeneity but did alter the overall inference (OR 0.42, 95% CI 0.27 to 0.65) however this was only based on two studies and 300 women (<a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). </p> </section> <section id="CD013505-sec-0112"> <h5 class="title">3.3 Ovulation rate</h5> <p>When we combined the data from seven studies (<a href="./references#CD013505-bbs2-0002" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMD . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD013505-bbs2-0012" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), we found that CC may improve ovulation rates slightly compared with metformin (OR 0.45, 95% CI 0.34 to 0.60; I<sup>2</sup> = 53%; 7 studies, 852 women; <a href="./references#CD013505-fig-0036" title="">Analysis 3.3</a>). </p> <p>Subgroup analysis by obesity status again showed evidence of a difference between the obese and non‐obese women (test for subgroup differences: Chi² = 11.69, df = 1 (P = 0.0006), I² = 91.4%). In the obese group, combining the results from <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> and <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> found improved ovulation rates with CC therapy (OR 0.29, 95% CI 0.20 to 0.43; I<sup>2</sup> = 0%; 2 studies, 500 women; low‐quality evidence). In the non‐obese group, the data were inconclusive (OR 0.80, 95% CI 0.52 to 1.25; I<sup>2</sup> = 0%; 5 studies, 352 women; low‐quality evidence). This suggests that the ovulation rate of non‐obese women with CC is 65%, which may change to between 49% and 70% with metformin, whereas the ovulation rate of obese women is 52%, which may decrease to between 18% to 31% with metformin. Sensitivity analysis by study quality did not change the inference (OR 0.38, 95% CI 0.26 to 0.55; 2 studies, 488 women) but did increase the heterogeneity (I<sup>2</sup> = 82%). We have presented ovulation rate per cycle in <a href="#CD013505-tbl-0008">Table 5</a>. </p> </section> <section id="CD013505-sec-0113"> <h5 class="title">3.4 Miscarriage rate and 3.5 Miscarriage (sensitivity analysis)</h5> <p>We found no evidence that metformin compared with CC increased miscarriage rates across both BMI groups (OR 0.92, 95% CI 0.51 to 1.66; I<sup>2</sup> = 36%; 6 studies, 781 women; low‐quality evidence; <a href="./references#CD013505-fig-0037" title="">Analysis 3.4</a>). On subgroup analysis of BMI, the test for subgroup differences showed no evidence of a difference between obese and non‐obese women (P = 0.14). This suggests that the miscarriage rate of non‐obese women with CC is 6%, which may change to between 4% and 18% with metformin, whereas the miscarriage rate of obese women is 6%, which may change to between 2% to 9% with metformin. Sensitivity analysis by study quality did not change the inference but did increase the heterogeneity (I<sup>2</sup> = 71%). </p> <p>Analysis of miscarriage rate per pregnancy showed no clear evidence of a difference between the groups (OR 1.36, 95% CI 0.69 to 2.66; I<sup>2</sup> = 60%; 6 studies, 203 pregnancies; <a href="./references#CD013505-fig-0038" title="">Analysis 3.5</a>), still with no evidence of a difference between the BMI subgroups (P = 0.36). </p> </section> <section id="CD013505-sec-0114"> <h5 class="title">3.6 Multiple pregnancy rate and 3.7 Multiple pregnancy rate per pregnancy</h5> <p>We are uncertain of the effect of metformin compared with CC on multiple pregnancy rates (OR 0.29, 95% CI 0.06 to 1.43; I<sup>2</sup> = 0%; 5 studies, 858 women; <a href="./references#CD013505-fig-0039" title="">Analysis 3.6</a>). In the subgroup analysis by obesity status, there was no evidence of a difference between the subgroups (P = 0.52). Sensitivity analysis by study quality did not change the inference or heterogeneity. </p> <p>Analysis of multiple pregnancy rate per pregnancy showed no clear evidence of a difference between metformin compared with CC (OR 0.33, 95% CI 0.06 to 1.68; I<sup>2</sup> = 0%; 5 studies, 201 pregnancies; <a href="./references#CD013505-fig-0040" title="">Analysis 3.7</a>). </p> </section> <section id="CD013505-sec-0115"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0116"> <h6 class="title">3.8 Body mass index</h6> <p>Only one study reported BMI (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>), which suggested that metformin did reduce BMI compared with CC (MD −5.10, 95% CI −9.40 to −0.80; 40 women; <a href="./references#CD013505-fig-0041" title="">Analysis 3.8</a>), however this is insufficient evidence to draw conclusions. </p> </section> </section> <section id="CD013505-sec-0117"> <h5 class="title">Endocrine outcomes</h5> <section id="CD013505-sec-0118"> <h6 class="title">3.9 Serum testosterone</h6> <p>Only one study reported serum testosterone (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>), which found no effect of metformin on testosterone levels compared with CC (MD 0.30, 95% CI −0.82 to 1.42; 40 women; <a href="./references#CD013505-fig-0042" title="">Analysis 3.9</a>), however this is insufficient evidence to draw any conclusions. </p> </section> <section id="CD013505-sec-0119"> <h6 class="title">Serum sex hormone‐binding globulin</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0120"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0121"> <h6 class="title">3.10 Fasting glucose</h6> <p>Only one study reported fasting blood glucose (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>), which found no effect of metformin on fasting blood glucose levels compared with CC (MD −0.20, 95% CI −0.79 to 0.39; 40 women; <a href="./references#CD013505-fig-0043" title="">Analysis 3.10</a>) however this is insufficient evidence to draw any conclusions. </p> </section> <section id="CD013505-sec-0122"> <h6 class="title">3.11 Fasting insulin</h6> <p>Only one study reported fasting insulin levels (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>), which found a reduction in fasting insulin with metformin compared with CC (MD −13.00, 95% CI −16.96 to −9.04; 40 women; <a href="./references#CD013505-fig-0044" title="">Analysis 3.11</a>), although this is insufficient evidence to draw any conclusions. </p> </section> </section> </section> <section id="CD013505-sec-0123"> <h4 class="title">4. Metformin and letrozole versus letrozole</h4> <section id="CD013505-sec-0124"> <h5 class="title">4.1 Live birth rate</h5> <p>Only one study reported live birth rate (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), and there was an identical number of live births in each group (OR 1.00, 95% CI 0.48 to 2.08; 134 women; <a href="./references#CD013505-fig-0045" title="">Analysis 4.1</a>), however this is insufficient evidence to draw any conclusions. </p> </section> <section id="CD013505-sec-0125"> <h5 class="title">4.2 Adverse events (gastrointestinal side effects)</h5> <p>Only one study reported gastrointestinal adverse events (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), and found no clear evidence that women taking combined metformin and letrozole had more side effects than with letrozole alone (OR 16.74, 95% CI 0.94 to 299.23; 134 women; <a href="./references#CD013505-fig-0046" title="">Analysis 4.2</a>). Seven of 67 women suffered gastrointestinal side effects with metformin and letrozole compared with 0 of 67 women with letrozole alone. </p> </section> <section id="CD013505-sec-0126"> <h5 class="title">4.3 Clinical pregnancy rate</h5> <p>Only one study reported clinical pregnancy rate (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), which found no clear evidence that women who had both metformin and letrozole had an improved clinical pregnancy rate compared with letrozole alone (OR 1.27, 95% CI 0.64 to 2.51; 134 women; <a href="./references#CD013505-fig-0047" title="">Analysis 4.3</a>), however the data are insufficient to allow us to draw conclusions. </p> </section> <section id="CD013505-sec-0127"> <h5 class="title">Ovulation rate</h5> <p>Data were not available for this outcome. Data for ovulation per cycle are available and presented in <a href="#CD013505-tbl-0009">Table 6</a>. </p> </section> <section id="CD013505-sec-0128"> <h5 class="title">4.4 Miscarriage rate and 4.5 Miscarriage rate per pregnancy</h5> <p>Only one study reported miscarriage rate (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), which found no difference in miscarriage rate between the two treatment groups (OR 1.61, 95% CI 0.61 to 4.23; 134 women; <a href="./references#CD013505-fig-0048" title="">Analysis 4.4</a>) however this is insufficient evidence to draw conclusions. </p> <p>Sensitivity analysis of miscarriage per pregnancy did not show clear evidence of a difference between metformin and letrozole compared with letrozole alone (OR 1.50, 95% CI 0.51 to 4.42; 62 pregnancies; <a href="./references#CD013505-fig-0049" title="">Analysis 4.5</a>). </p> </section> <section id="CD013505-sec-0129"> <h5 class="title">Multiple pregnancy rate</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0130"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0131"> <h6 class="title">Body mass index</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0132"> <h5 class="title">Endocrine outcomes</h5> <section id="CD013505-sec-0133"> <h6 class="title">Serum testosterone</h6> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0134"> <h6 class="title">Serum sex hormone‐binding globulin</h6> <p>Data were not available for this outcome</p> </section> </section> <section id="CD013505-sec-0135"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0136"> <h6 class="title">Fasting glucose</h6> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0137"> <h6 class="title">Fasting insulin</h6> <p>Data were not available for this outcome.</p> </section> </section> </section> <section id="CD013505-sec-0138"> <h4 class="title">Metformin versus letrozole</h4> <p>We did not identify any suitable studies for this comparison.</p> </section> <section id="CD013505-sec-0139"> <h4 class="title">5 Metformin and LOD versus LOD</h4> <section id="CD013505-sec-0140"> <h5 class="title">5.1 Live birth rate</h5> <p>Only one study reported live birth rate (<a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>), which found no clear evidence of a difference between metformin and LOD compared with LOD alone (OR 2.13, 95% CI 0.51 to 8.77; 42 women; <a href="./references#CD013505-fig-0050" title="">Analysis 5.1</a>), although the data are insufficient to allow us to draw conclusions. </p> </section> <section id="CD013505-sec-0141"> <h5 class="title">Adverse events (gastrointestinal side effects)</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0142"> <h5 class="title">5.2 Clinical pregnancy rate</h5> <p>Only one study reported clinical pregnancy rate (<a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>), which found no clear evidence of a difference between metformin and LOD compared with LOD alone (OR 3.19, 95% CI 0.79 to 12.80; 42 women; <a href="./references#CD013505-fig-0051" title="">Analysis 5.2</a>), although the data are insufficient to allow us to draw conclusions. </p> </section> <section id="CD013505-sec-0143"> <h5 class="title">Ovulation rate</h5> <p>Data were not available for this outcome. We have presented data for ovulation per cycle in <a href="#CD013505-tbl-0010">Table 7</a>. </p> </section> <section id="CD013505-sec-0144"> <h5 class="title">5.3 Miscarriage rate and 5.4 Miscarriage rate per pregnancy</h5> <p>Only one study reported miscarriage rate (<a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a>), which found no clear evidence of a difference between metformin and LOD compared with LOD alone (OR 5.51, 95% CI 0.25 to 122.08; <a href="./references#CD013505-fig-0052" title="">Analysis 5.3</a>), although the data are insufficient to allow us to draw conclusions. </p> <p>Sensitvity analysis of miscarriage per pregnancy found no clear evidence of a difference between metformin and LOD compared with LOD alone (OR 3.00, 95% CI 0.12 to 77.64; 13 pregnancies; <a href="./references#CD013505-fig-0053" title="">Analysis 5.4</a>). </p> </section> <section id="CD013505-sec-0145"> <h5 class="title">Multiple pregnancy rate</h5> <p>Data were not available for this outcome</p> </section> <section id="CD013505-sec-0146"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0147"> <h6 class="title">Body mass index</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0148"> <h5 class="title">Endocrine outcomes</h5> <section id="CD013505-sec-0149"> <h6 class="title">Serum testosterone</h6> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0150"> <h6 class="title">Serum sex hormone‐binding globulin</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0151"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0152"> <h6 class="title">Fasting glucose</h6> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0153"> <h6 class="title">Fasting insulin</h6> <p>Data were not available for this outcome.</p> </section> </section> </section> <section id="CD013505-sec-0154"> <h4 class="title">6. Metformin versus LOD</h4> <section id="CD013505-sec-0155"> <h5 class="title">6.1 Live birth rate</h5> <p>Only one study reported live birth rate (<a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), which found live birth rate to be improved in the metformin group compared with LOD (OR 2.29, 95% CI 1.09 to 4.78; 120 women; <a href="./references#CD013505-fig-0054" title="">Analysis 6.1</a>). </p> </section> <section id="CD013505-sec-0156"> <h5 class="title">6.2 Adverse events (gastrointestinal side effects)</h5> <p>Two studies reported gastrointestinal events (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), and found that the LOD group had fewer adverse side effects compared with metformin (OR 7.77, 95% CI 2.43 to 24.89; 230 women; <a href="./references#CD013505-fig-0055" title="">Analysis 6.2</a>). <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a> included non‐obese women and <a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a> included obese women, however there was no difference between the groups (test for subgroup differences: Chi² = 1.10, df = 1 (P = 0.30), I² = 8.8%). </p> </section> <section id="CD013505-sec-0157"> <h5 class="title">6.3 Clinical pregnancy rate</h5> <p>Two studies reported clinical pregnancy rate (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), and we are uncertain of the effect of metformin compared with LOD on clinical pregnancy rate (OR 0.93, 95% CI 0.54 to 1.59; 2 studies, 230 women; <a href="./references#CD013505-fig-0056" title="">Analysis 6.3</a>). </p> <p>Subgroup analysis showed a significant difference between the obese and the non‐obese group (test for subgroup difference: Chi² = 6.42, df = 1 (P = 0.01), I² = 84.4%) where obese women favoured LOD (OR 0.40, 95% CI 0.17 to 0.95; 1 study, 110 women). </p> </section> <section id="CD013505-sec-0158"> <h5 class="title">6.4 Ovulation rate</h5> <p>Only one study reported ovulation per woman (<a href="./references#CD013505-bbs2-0025" title="MalkawiHY , QublanHS , HamaidehAH . Medical vs. surgical treatment for clomiphene citrate‐resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology2003;23(3):289‐93. ">Malkawi 2003</a>), and we are uncertain of the effect of metformin compared with LOD on ovulation rate (OR 0.51, 95% CI 0.26 to 1.01; 145 women; <a href="./references#CD013505-fig-0057" title="">Analysis 6.4</a>). </p> <p>Two studies reported data for ovulation per cycle, which we have presented in <a href="#CD013505-tbl-0011">Table 8</a>. </p> <div class="table" id="CD013505-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Metformin vs laparoscopic ovarian drilling (LOD): ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013505-sec-0159"> <h5 class="title">6.5 Miscarriage rate and 6.6 Miscarriage per pregnancy</h5> <p>Two studies reported miscarriage rate (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>; <a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), and found no evidence of an effect of metformin compared with LOD for miscarriage rate (OR 0.58, 95% CI 0.23 to 1.47; 2 studies, 230 women; <a href="./references#CD013505-fig-0058" title="">Analysis 6.5</a>). Subgroup analysis found no clear evidence of a difference between obese and non‐obese women (test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.80), I² = 0%). </p> <p>Sensitvity analysis of miscarriage per pregnancy found no clear evidence of a difference between metformin and LOD (OR 0.55, 95% CI 0.20 to 1.48; 2 studies, 102 pregnancies; <a href="./references#CD013505-fig-0059" title="">Analysis 6.6</a>). </p> </section> <section id="CD013505-sec-0160"> <h5 class="title">Multiple pregnancy rate</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0161"> <h5 class="title">Anthropometric outcomes</h5> <section id="CD013505-sec-0162"> <h6 class="title">6.7 Body mass index</h6> <p>One study reported BMI (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>), and we are uncertain of the effect of metformin versus LOD on BMI (MD −3.60, 95% CI −13.48 to 6.28; 110 women; <a href="./references#CD013505-fig-0060" title="">Analysis 6.7</a>). </p> </section> </section> <section id="CD013505-sec-0163"> <h5 class="title">6.8 Endocrine outcomes</h5> <section id="CD013505-sec-0164"> <h6 class="title">Serum testosterone</h6> <p>One study reported serum testosterone (<a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a>), and we are uncertain of the effect of metformin versus LOD on serum testosterone (MD −0.16, 95% CI −1.09 to 0.77; 110 women; <a href="./references#CD013505-fig-0061" title="">Analysis 6.8</a>). </p> </section> <section id="CD013505-sec-0165"> <h6 class="title">Serum sex hormone‐binding globulin</h6> <p>Data were not available for this outcome.</p> </section> </section> <section id="CD013505-sec-0166"> <h5 class="title">Metabolic outcomes</h5> <section id="CD013505-sec-0167"> <h6 class="title">Fasting glucose</h6> <p>Data were not available for this outcome.</p> </section> <section id="CD013505-sec-0168"> <h6 class="title">Fasting insulin</h6> <p>Data were not available for this outcome.</p> </section> </section> </section> <section id="CD013505-sec-0169"> <h4 class="title">Publication bias</h4> <p>We assessed publication bias using a funnel plot (<a href="#CD013505-fig-0007">Figure 7</a>; <a href="./full#CD013505-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD013505-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013505-tbl-0003">summary of findings Table 3</a>). </p> <div class="figure" id="CD013505-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Metformin and clomiphene citrate versus clomiphene citrate alone, outcome: 2.4 Ovulation rate." data-id="CD013505-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Metformin and clomiphene citrate versus clomiphene citrate alone, outcome: 2.4 Ovulation rate. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013505-sec-0170" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013505-sec-0170"></div> <section id="CD013505-sec-0171"> <h3 class="title" id="CD013505-sec-0171">Summary of main results</h3> <p>Metformin is associated with a beneficial effect on ovulation and clinical pregnancy rates, regardless of BMI, when compared with placebo. This update did not yield any further studies comparing metformin to placebo for live birth rate and therefore more high‐quality studies that report live birth as a primary outcome are still required. When comparing outcomes following the use of metformin or CC, higher ovulation rates suggest that CC is beneficial over metformin, in particular in women with a BMI of 30 kg/m<sup>2</sup> or higher. However, there was no clear evidence to suggest that either treatment would increase the likelihood of a live birth or clinical pregnancy rate over the other. </p> <p>Women who are known to be resistant to CC therapy may benefit from improved ovulation with the addition of metformin to CC. However, data were not available to determine if this would improve clinical pregnancy or live birth rates in this group of women. Women taking metformin should be advised that there does not appear to be an effect on miscarriage with treatment, but the likelihood of gastrointestinal side effects is higher than with placebo or CC. More studies that compare the effects of ovulation‐induction agents with CC‐resistant versus CC‐sensitive women are required. </p> <p>There was insufficient evidence to determine a beneficial effect with metformin compared with or in combination with letrozole for live birth rate, clinical pregnancy or ovulation. There is some evidence that metformin is beneficial over LOD for improving live birth rate however this was based on one study and the findings did not correlate for clinical pregnancy and ovulation rate. </p> <section id="CD013505-sec-0172"> <h4 class="title">Reproductive outcomes</h4> <p>When compared with placebo, the results suggest a possible benefit of using metformin in improving live birth rates (<a href="./references#CD013505-fig-0008" title="">Analysis 1.1</a>). One high‐quality study included in this updated review contributed the majority of the weight (89.2%) to this finding (<a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a>). However, the wide‐ranging confidence intervals and lower‐quality evidence when the <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a> results were combined with other included studies, makes the advantage offered by metformin difficult to interpret clinically. However, clinical pregnancy rates were higher with the use of metformin for ovulation induction (<a href="./references#CD013505-fig-0010" title="">Analysis 1.3</a>). Ovulation also appeared to be improved with metformin versus placebo, which persisted following a subgroup analysis by BMI (<a href="./references#CD013505-fig-0011" title="">Analysis 1.4</a>). </p> <p>There was no conclusive evidence that adding metformin in combination with CC, increased live birth compared with CC monotherapy (<a href="./references#CD013505-fig-0021" title="">Analysis 2.1</a>). However, clinical pregnancy and ovulation rates were improved with combination treatment in both BMI groups (<a href="./references#CD013505-fig-0023" title="">Analysis 2.3</a>; <a href="./references#CD013505-fig-0024" title="">Analysis 2.4</a>). We attempted to analyse data depending on whether women were known to be sensitive or resistant to CC. Unfortunately, these data were only available for ovulation rate. In women who are CC‐resistant, improved ovulation rate was seen with adding metformin to CC compared to women who were CC‐sensitive (<a href="./references#CD013505-fig-0025" title="">Analysis 2.5</a>). </p> <p>When metformin was compared with CC, findings were complicated by a difference based on the obesity status of the participants. Here, women in the non‐obese group were more likely to achieve a live birth with metformin, whilst the obese women appeared to benefit from CC therapy (<a href="./references#CD013505-fig-0034" title="">Analysis 3.1</a>). This pattern was also evident for clinical pregnancy (<a href="./references#CD013505-fig-0035" title="">Analysis 3.2</a>), however, the studies in this review failed to show the same pattern with ovulation rate. There was evidence to suggest that CC increased ovulation rate compared with metformin for both obese and non‐obese groups, although the evidence in non‐obese groups was less clear (<a href="./references#CD013505-fig-0036" title="">Analysis 3.3</a>). </p> <p>We did not find any eligible studies that compared metformin with letrozole directly. When metformin and letrozole in combination were compared with letrozole alone, there was insufficient evidence to suggest that adding metformin improved live birth or clinical pregnancy rates (<a href="./references#CD013505-fig-0045" title="">Analysis 4.1</a>; <a href="./references#CD013505-fig-0047" title="">Analysis 4.3</a>). We did not find any data on ovulation rate for these comparisons. </p> <p>When adding metformin to LOD compared with LOD alone, there was no evidence to suggest an improvement in live birth rate or clinical pregnancy rate (<a href="./references#CD013505-fig-0050" title="">Analysis 5.1</a>; <a href="./references#CD013505-fig-0051" title="">Analysis 5.2</a>). We did not find any data on ovulation rate for these comparisons. When comparing metformin directly with LOD, there was evidence to suggest benefit with metformin compared with LOD for live birth rate however this was based on only one study (<a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>; <a href="./references#CD013505-fig-0054" title="">Analysis 6.1</a>). There was insufficient evidence to suggest a benefit with metformin compared with LOD for clinical pregnancy rate (<a href="./references#CD013505-fig-0055" title="">Analysis 6.2</a>). </p> <p>Miscarriage was not commonly reported as an outcome and when it was reported, the event rate was low (4.8%, 223 miscarriages of 4552 women). There was no evidence of an effect with metformin compared with placebo, with combined metformin and CC compared with CC alone or with metformin versus CC directly (<a href="./references#CD013505-fig-0012" title="">Analysis 1.5</a>; <a href="./references#CD013505-fig-0026" title="">Analysis 2.6</a>; <a href="./references#CD013505-fig-0037" title="">Analysis 3.4</a>). The previous review suggested an increase in miscarriage when CC combined with metformin was compared with CC alone. However, we did not see this effect in the current review with the addition of three new studies (<a href="./references#CD013505-bbs2-0020" title="LiuZ , Xue , Y , ChenL , CaiQ , ChenH , ZhangJ , et al. Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome. Chinese Journal of Obstetrics and Gynaecology2004;39(9):586‐90. ">Liu 2004</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>). The results were inconclusive for miscarriage rates for metformin and letrozole versus letrozole, metformin and LOD versus LOD, or metformin versus LOD (<a href="./references#CD013505-fig-0048" title="">Analysis 4.4</a>; <a href="./references#CD013505-fig-0052" title="">Analysis 5.3</a>; <a href="./references#CD013505-fig-0058" title="">Analysis 6.5</a>). </p> <p>For the multiple pregnancy outcome, there was only one study that reported multiple pregnancy rates for metformin compared with placebo and no available data regarding metformin and letrozole versus letrozole, metformin and LOD versus LOD or metformin versus LOD. The results were inconclusive for combination therapy versus CC monotherapy, and for the comparison between metformin and CC (<a href="./references#CD013505-fig-0028" title="">Analysis 2.8</a>; <a href="./references#CD013505-fig-0039" title="">Analysis 3.6</a>). </p> </section> <section id="CD013505-sec-0173"> <h4 class="title">Adverse effects</h4> <p>Metformin was associated with higher rates of gastrointestinal side effects compared with placebo and LOD (<a href="./references#CD013505-fig-0009" title="">Analysis 1.2</a>; <a href="./references#CD013505-fig-0055" title="">Analysis 6.2</a>). Combination treatment of metformin and CC also had increased rates of gastrointestinal side effects compared with CC alone (<a href="./references#CD013505-fig-0022" title="">Analysis 2.2</a>). There were insufficient data available for metformin compared with CC or letrozole directly, and for when metformin was used in combination with letrozole and LOD. </p> </section> <section id="CD013505-sec-0174"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>This review included studies that specifically reported reproductive outcomes where women had taken metformin in an attempt to induce ovulation and conceive. We excluded studies that compared metformin to placebo to improve BMI or other metabolic outcomes only, without attempting to induce ovulation. Therefore we cannot provide a robust analysis of the effect of metformin compared to placebo on metabolic and anthropometric outcomes. Nonetheless, we did analyse the metabolic and anthropometric outcomes within these included studies for all comparisons that were relevant in view of reducing the risk of metabolic syndrome and associated complications of cardiovascular risk and type 2 diabetes mellitus, which can increase maternal and fetal morbidity and mortality. These outcomes include BMI, serum testosterone, serum sex hormone‐binding globulin, fasting insulin and fasting glucose. There was no evidence that metformin reduced BMI when compared with placebo (<a href="./references#CD013505-fig-0016" title="">Analysis 1.9</a>), and there was no significant difference between BMI subgroups. However, there was some evidence to suggest that metformin might reduce BMI when added to CC compared with CC alone as well as when compared with metformin directly (<a href="./references#CD013505-fig-0030" title="">Analysis 2.10</a>; <a href="./references#CD013505-fig-0041" title="">Analysis 3.8</a>). There was no evidence to suggest a beneficial effect when metformin was compared with LOD directly (<a href="./references#CD013505-fig-0060" title="">Analysis 6.7</a>), and there were no data available for metformin and letrozole compared with letrozole alone, nor metformin and LOD compared with LOD alone. The insufficient data across many of these comparators is likely due to the restrictions of only including studies with reproductive outcomes. The Australian National Health and Medical Research Council (NHRMC) reported that the use of metformin, not specifically for ovulation induction, improves metabolic and anthropometric outcomes including lowering BMI, testosterone, fasting insulin and cholesterol levels (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). </p> <p>With regards to endocrine outcomes, there was evidence to suggest a reduction in serum testosterone levels with metformin compared with placebo (<a href="./references#CD013505-fig-0017" title="">Analysis 1.10</a>), however, we did not see the same effect when we compared metformin and CC with CC alone, or metformin with CC or LOD (<a href="./references#CD013505-fig-0031" title="">Analysis 2.11</a>; <a href="./references#CD013505-fig-0042" title="">Analysis 3.9</a>; <a href="./references#CD013505-fig-0061" title="">Analysis 6.8</a>). Serum sex hormone‐binding globulin was only measured in the metformin versus placebo group and there was no evidence to suggest a benefit of using metformin compared with placebo (<a href="./references#CD013505-fig-0018" title="">Analysis 1.11</a>). </p> <p>There was no conclusive evidence of an effect of metformin on serum glucose levels (<a href="./references#CD013505-fig-0019" title="">Analysis 1.12</a>; <a href="./references#CD013505-fig-0032" title="">Analysis 2.12</a>; <a href="./references#CD013505-fig-0043" title="">Analysis 3.10</a>). There was no conclusive evidence of an effect of metformin when compared with placebo for reducing serum insulin levels (<a href="./references#CD013505-fig-0020" title="">Analysis 1.13</a>) however, there was some evidence of an effect of metformin on reducing serum insulin levels when added to CC therapy compared with CC alone and when compared directly to CC (<a href="./references#CD013505-fig-0033" title="">Analysis 2.13</a>; <a href="./references#CD013505-fig-0044" title="">Analysis 3.11</a>). </p> <p>It is therefore unclear whether these metabolic and endocrine effects would be of clinical benefit in reducing the risk of metabolic syndrome in women with PCOS, especially given that data on these outcomes were associated with high heterogeneity and some of the effects were created from single small studies. Furthermore, 11 studies included specific advice on lifestyle modification in the study protocol (<a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD013505-bbs2-0014" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>; <a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). Obesity has a significant detrimental impact on both maternal and fetal outcomes in pregnancy as well as longer‐term cardiovascular health (<a href="./references#CD013505-bbs2-0105" title="CedergrenMI . Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstetrics and Gynecology2004;103:219‐24. ">Cedergren 2004</a>). As such, women with PCOS should still be advised to undergo lifestyle interventions before any fertility treatment (<a href="./references#CD013505-bbs2-0116" title="The Thessaloniki ESHRE/ASRM‐sponsored PCOS consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction2008;23:462‐77. ">ESHRE/ASRM 2008</a>). </p> </section> <section id="CD013505-sec-0175"> <h4 class="title">Limitations</h4> <p>See <a href="#CD013505-sec-0179">Quality of the evidence</a> and <a href="#CD013505-sec-0180">Potential biases in the review process</a>. </p> </section> </section> <section id="CD013505-sec-0176"> <h3 class="title" id="CD013505-sec-0176">Overall completeness and applicability of evidence</h3> <p>This review includes a large number of women, all meeting the Rotterdam diagnostic criteria for PCOS (<a href="./references#CD013505-bbs2-0115" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). However, we still observed significant heterogeneity in many of the analyses. This was particularly evident in the biochemical outcomes, even after adjustment for BMI, dosage of metformin and duration of treatment. Heterogeneity remained unchanged after sensitivity analysis by study quality. However, the prevalence and magnitude of insulin resistance are influenced by ethnicity (<a href="./references#CD013505-bbs2-0127" title="KakolyNS , KhomamiMB , JohamAE , CooraySD , MissoML , NormanRJ , et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta‐regression. Human Reproduction Update2018;24:455‐67. ">Kakoly 2018</a>), therefore, combining trials from different study populations would introduce heterogeneity despite all meeting the diagnostic criteria of PCOS. Another factor is the range of biochemical assays used in different studies, which may introduce some heterogeneity. The efficacy of metformin in PCOS was first described by <a href="./references#CD013505-bbs2-0157" title="VelazquezE , AcostaA , MendozaSG . Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology1997;90:392‐5. ">Velazquez 1997</a>. A number of small, and often short‐duration, observational studies followed, which showed variable outcomes. Indeed, in a systematic review by <a href="./references#CD013505-bbs2-0108" title="CostelloMF , EdenJA . A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertility and Sterility2003;79:1‐13. ">Costello 2003</a> nine out of the 12 published studies on the effects of metformin alone on the menstrual cycle in women with PCOS had a sample size of fewer than 30 women. The first Cochrane Review by <a href="./references#CD013505-bbs2-0131" title="LordJ , WilkinT . Polycystic ovary syndrome and fat distribution: the central issue?. Human Fertility (Cambridge)2002;5:67‐71. ">Lord 2002</a> included nearly 1000 women from 15 RCTs. However, most of the studies had relatively small sample sizes with the largest one containing 94 women (<a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>). In this fourth updated review, we included 41 RCTs (4552 women), with the two largest studies of high quality being by <a href="./references#CD013505-bbs2-0027" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐500. ">Morin‐Papunen 2012</a> and <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>, with sample sizes of 320 and 626 women, respectively. </p> <section id="CD013505-sec-0177"> <h4 class="title">Reproductive outcomes</h4> <p>This review focused on the effect of metformin on reproductive outcomes including ovulation rate, clinical pregnancy rate and live birth rate. </p> <p>This review confirmed the findings from the previous review that there is a potential benefit of using metformin when compared with placebo to improve live birth rate, with a number needed to treat for an additional beneficial outcome of 13. This positive finding was consistent in both obese and non‐obese women. Similar findings were seen with ovulation rate and clinical pregnancy rate, which further strengthens any recommendation to use metformin compared with placebo for ovulation induction in PCOS women with subfertility. However, the impact on live birth rate was based on four studies, the majority with low‐quality evidence and we were unable to obtain any new studies to strengthen the recommendation. We included two additional studies featuring data on ovulation and clinical pregnancy rate (<a href="./references#CD013505-bbs2-0005" title="ChuniN . Efficacy of sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome. Journal of Obstetrics and Gynecology of India2007;57(1):69‐72. ">Chuni 2006</a>; <a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>). Obese women with PCOS have higher levels of insulin resistance and higher serum insulin concentrations and hence metformin may have a limited effect on reducing these high serum insulin concentrations in the obese group compared with non‐obese women (<a href="./references#CD013505-bbs2-0038" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). Further studies comparing metformin with placebo must stratify by BMI in order to guide the use of metformin appropriately. </p> <p>Traditionally, CC is the first‐line therapy for ovulation induction in PCOS women. In this review, we did not find any additional studies with data on live birth rates when directly comparing metformin and CC. Of the five studies included, the results differed with BMI. CC increased live births in the obese group, with a large weighting from the study by <a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>. In the non‐obese group however, metformin appeared to increase live births yet this analysis included only small studies of low quality. The same inference was seen with clinical pregnancy rate. More high‐quality studies are required with larger numbers of participants to assess metformin versus CC for live birth rate. </p> <p>The addition of two new studies (<a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a>; <a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>), did not change the inference that there was no clear evidence of improvement in live birth rate with combination metformin and CC compared with CC alone. However, there was evidence to suggest improvement in clinical pregnancy and ovulation rates. Similarly to the previous review, a larger effect was seen in the CC‐resistant group compared with the CC‐sensitive group, with low heterogeneity (I<sup>2</sup> = 0%) in the CC‐resistant group. However, the CC‐sensitive group consisted of one study only (<a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>). Future studies to determine the effect of metformin compared with CC on live birth rate should specify CC sensitivity. Within the BMI subgroups, heterogeneity was high for both groups and there was no difference in effect between obese and non‐obese women (P = 0.16). </p> <p>In this review, there was no evidence of an effect with miscarriage or multiple pregnancy rates attributable to metformin. However, women should be counselled on the increased gastrointestinal side effects associated with metformin use. </p> <p>We did not find any eligible studies that directly compared metformin with aromatase inhibitors. One study compared combined metformin and letrozole with letrozole alone, although there was insufficient evidence of a beneficial effect on live birth rate, clinical pregnancy, miscarriage or adverse effects (<a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a>). The study had an unclear risk of bias and larger studies of higher‐quality are required to determine the effect of metformin compared with letrozole. </p> <p>We found three studies that directly compared metformin with LOD. There was evidence to suggest that metformin had a beneficial effect on live birth rate compared with LOD. However, only one small study reported this outcome (<a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), and hence more studies that report live birth rate are required. Furthermore, the findings do not correlate with other reproductive outcomes where there was insufficient evidence to suggest a beneficial effect with metformin compared with LOD for clinical pregnancy rate and ovulation rate. Of the three studies, only one study (<a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), showed low risk of bias and hence more, larger, high‐quality studies are required to clarify the uncertainty that these pooled results reveal on the effect of metformin compared with LOD. One study analysed the cost effectiveness of LOD compared with metformin (<a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a>), who compared the costs of the day‐surgery fee, the surgeon's fee, the anaesthetist's fee, assistant's fee as well as the equipment required for LOD with the cost of six cycles of metformin given at 1700 mg daily. The cost of LOD was significantly more expensive (EUR 1050) compared with the six‐month course of metformin (EUR 50; P &lt; 0.05). This paper was published 15 years prior to this review and hence now we could expect an even greater discrepancy between medical versus surgical management. Hence, it is important to consider the cost effectiveness of medical versus surgical treatment especially in low‐income countries where access to surgery may be less easy. </p> </section> <section id="CD013505-sec-0178"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>There is still no long‐term data available on the use of metformin for women with PCOS in reducing the risk of developing diabetes or metabolic syndrome. This review found no evidence of an effect of metformin on reducing BMI when compared with placebo. Some reduction of BMI was seen when metformin was added to CC therapy and when compared with CC, although these results were based on small studies with unclear risks of bias. Testosterone levels were reduced with metformin therapy compared with placebo, although heterogeneity was high (I<sup>2</sup> = 94%), which makes this finding difficult to interpret clinically. Other comparisons did not show an effect on testosterone levels nor serum insulin or serum glucose because only small numbers of low‐quality studies were available for analysis. </p> </section> </section> <section id="CD013505-sec-0179"> <h3 class="title" id="CD013505-sec-0179">Quality of the evidence</h3> <p>Overall, we graded only 12 out of the 41 included studies as having a low risk of bias to sequence generation, allocation concealment and blinding. The main limitation of the comparisons in this review is therefore the risk of bias and imprecision within the included studies, as discussed in '<a href="./full#CD013505-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD013505-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013505-tbl-0003">summary of findings Table 3</a> and <a href="#CD013505-fig-0002">Figure 2</a> and <a href="#CD013505-fig-0003">Figure 3</a>. However, sensitivity analysis on the studies with adequate sequence generation, allocation concealment and blinding method did not alter the clinical findings. We classified the overall quality of evidence for metformin versus placebo as low for live birth rate, ovulation rate and miscarriage rate, and moderate for clinical pregnancy rate and adverse effects (<a href="./full#CD013505-tbl-0001">summary of findings Table for the main comparison</a>). This was due to a moderate risk of bias, marginal effect size and statistical imprecision. Despite many comparison studies demonstrating high heterogeneity, we did not downgrade if the direction of effect was consistent, nor if the heterogeneity was attributable to a single study. We regarded both the evidence for metformin and letrozole compared with letrozole, as well as metformin combined with LOD versus LOD alone as low quality, based on a single study only. The overall quality of evidence for metformin versus LOD was also low. </p> </section> <section id="CD013505-sec-0180"> <h3 class="title" id="CD013505-sec-0180">Potential biases in the review process</h3> <p>We conducted a thorough search, used sound methodology and are not aware of any biases in the review process. </p> <p>There are some papers awaiting classification (<a href="./references#CD013505-bbs2-0084" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin–clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6(2):198‐201. ">Ayaz 2013a</a>; <a href="./references#CD013505-bbs2-0085" title="BeigiA . Randomized trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in polycystic ovary syndrome. Human Reproduction2006;21(i129):[Abstract]. ">Beigi 2006</a>; <a href="./references#CD013505-bbs2-0086" title="JahanS . Comparative study of efficacy among metformin, clomiphene citrate and aromatase inhibitor (letrozole) as the first‐line medication for ovulation induction, achievement of pregnancy and live birth in Asian women with polycystic ovarian syndrome: a prospective trial.. International Journal of Gynecology and Obstetrics2015;131(E503):[Abstract]. ">Jahan 2015</a>; <a href="./references#CD013505-bbs2-0087" title="RobinsonRD , SwezeyM , PropstA , BatesGW . Metformin added to clomiphene citrate does not improve pregnancy rates in hyperandrogenic, chronic anovulatory women: a randomized trial. Fertility and Sterility2003;80(3):S273‐S274, P‐464 [Abstract]. ">Robinson 2003</a>; <a href="./references#CD013505-bbs2-0088" title="SinghI , BedaiwyMA , HatwalA , KumarA , AgarwalA . Increased pregnancy rates with metformin and clomiphene citrate in non‐obese patients with polycystic ovary syndrome: prospective randomized study. Fertility and Sterility2001;76(3):Suppl 1, SP‐S94 [Abstract]. ">Singh 2001</a>; <a href="./references#CD013505-bbs2-0089" title="WilliamsCD , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92(3):S105 [Abstract]. ">Williams 2009</a>), and ongoing clinical trials (<a href="./references#CD013505-bbs2-0090" title="NCT00005104 . Randomized study of decreased hyperinsulinemia on the ovulatory response to clomiphene citrate in women with polycystic ovary syndrome. clinicaltrials.gov/ct2/show/NCT00005104(first posted April 2000). ">NCT00005104</a>; <a href="./references#CD013505-bbs2-0091" title="NCT00317928 . Efficacy of metformin in PCOS: metabolic and hormonal factors. clinicaltrials.gov/ct2/show/NCT00317928(first received April 2006). ">NCT00317928</a>; <a href="./references#CD013505-bbs2-0092" title="NCT00558077 . Second‐line treatments for anovulatory infertility in PCOS patients. clinicaltrials.gov/ct2/show/NCT00558077(first posted November 2007). ">NCT00558077</a>; <a href="./references#CD013505-bbs2-0093" title="NCT01679574 . Letrozole or combined clomiphene citrate metformin as a first line treatment in women with polycystic ovarian syndrome (PCO). clinicaltrials.gov/ct2/show/NCT01679574(first posted September 2012). ">NCT01679574</a>; <a href="./references#CD013505-bbs2-0094" title="NCT02562664 . Metformin improves clinical pregnancy rate in polycystic ovarian syndrome patients. clinicaltrials.gov/ct2/show/NCT02562664(first posted September 2015). ">NCT02562664</a>), that are likely to provide further useful information. </p> </section> <section id="CD013505-sec-0181"> <h3 class="title" id="CD013505-sec-0181">Agreements and disagreements with other studies or reviews</h3> <section id="CD013505-sec-0182"> <h4 class="title">Reproductive outcomes</h4> <p>A 2016 systematic review investigated the efficacy of metformin in women with anovulatory infertility for the improvement of reproductive outcomes (<a href="./references#CD013505-bbs2-0095" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a>). More recently, international guidelines have been released (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>), quoting results from the last Cochrane Review (<a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>), and with the addition of one more RCT, which has been included in this most current update (<a href="./references#CD013505-bbs2-0016" title="KjotrodSB , CarlsenSM , RasmussenPE , Holst‐LarsenT , MellembakkenJ , Thurin‐KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Human Reproduction2011;26(8):2045‐53. ">Kjotrod 2011</a>). The general consensus from these guidelines, which is in accordance with this update, is that metformin improves live birth rate, clinical pregnancy rate, ovulation rate, yet increases gastrointestinal side effects compared with placebo (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). Another recent meta‐analysis (<a href="./references#CD013505-bbs2-0160" title="WangR , LiW , BordeqijkEM , LegroRS , ZhangH , WuX , et al. First‐line ovulation induction for polycystic ovary syndrome: an individual participant data meta‐analysis. Human Reproduction Update2019;25:717‐32. ">Wang 2019</a>), found that CC and metformin may improve clinical pregnancy rate compared to CC alone (RR 1.18, 95% CI 1.00 to 1.39, 8 studies, 1039 women) however, there was insufficient evidence of a difference on live birth (RR 1.08, 95% CI 0.87 to 1.35, 5 studies, 907 women) These results are similar to this updated review however, <a href="./references#CD013505-bbs2-0160" title="WangR , LiW , BordeqijkEM , LegroRS , ZhangH , WuX , et al. First‐line ovulation induction for polycystic ovary syndrome: an individual participant data meta‐analysis. Human Reproduction Update2019;25:717‐32. ">Wang 2019</a> included fewer studies. Furthermore some of these studies involve intrauterine insemination and the use of hCG as an ovulation trigger, which we excluded from our review (<a href="./references#CD013505-bbs2-0062" title="LeanzaV , CocoL , GrassoF , LeanzaG , ZarboG , PalumboM . Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome. Minerva Ginecologica2014;66(3):299‐301. ">Leanza 2014;</a><a href="./references#CD013505-bbs2-0076" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics and Gynecology and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>). </p> <p>Comparison of metformin with CC for ovulation induction has been determined in three meta‐analyses as well as the recent international guidelines (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>; <a href="./references#CD013505-bbs2-0138" title="PalombaS , PasqualiR , Orio JrF , NestlerJE . Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clinical Endocrinology2009;70:311‐21. ">Palomba 2009</a>; <a href="./references#CD013505-bbs2-0149" title="SiebertTI , ViolaMI , SteynDW , KrugerTF . Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta‐analysis. Gynecologic and Obstetric Investigation2012;73:304‐13. ">Siebert 2012</a>; <a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a>). In accordance with our findings, they found improved ovulation rates with CC rather than metformin. There was no conclusive benefit of either treatment on clinical pregnancy or live birth rate, with wide confidence intervals noted. <a href="./references#CD013505-bbs2-0138" title="PalombaS , PasqualiR , Orio JrF , NestlerJE . Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clinical Endocrinology2009;70:311‐21. ">Palomba 2009</a> and <a href="./references#CD013505-bbs2-0149" title="SiebertTI , ViolaMI , SteynDW , KrugerTF . Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta‐analysis. Gynecologic and Obstetric Investigation2012;73:304‐13. ">Siebert 2012</a> therefore conclude that CC remains the “gold standard first‐line pharmacological treatment for ovulation induction in anovulatory infertile women with PCOS”. An analysis of four studies that compared metformin with CC in non‐obese women found no significant difference in reproductive outcomes (<a href="./references#CD013505-bbs2-0133" title="MissoML , CostelloMF , GarrubbaM , WongJ , HartR , RombautsL , et al. Metformin versus clomiphene citrate for infertility in non‐obese women with polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction Update2013;19:2‐11. ">Misso 2013</a>). The conclusions drawn by <a href="./references#CD013505-bbs2-0095" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> echo the ESHRE consensus, which documented that the first‐line treatment for anovulatory infertility is CC, whilst obese women should be advised to undergo lifestyle modifications (<a href="./references#CD013505-bbs2-0116" title="The Thessaloniki ESHRE/ASRM‐sponsored PCOS consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction2008;23:462‐77. ">ESHRE/ASRM 2008</a>). </p> <p>When evaluating the <a href="./references#CD013505-bbs2-0138" title="PalombaS , PasqualiR , Orio JrF , NestlerJE . Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clinical Endocrinology2009;70:311‐21. ">Palomba 2009</a> and <a href="./references#CD013505-bbs2-0149" title="SiebertTI , ViolaMI , SteynDW , KrugerTF . Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta‐analysis. Gynecologic and Obstetric Investigation2012;73:304‐13. ">Siebert 2012</a> meta‐analyses, <a href="./references#CD013505-bbs2-0095" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> found no evidence of an improvement in live birth when metformin was used in combination with CC. Our review also found no conclusive evidence of a difference in live birth rate, although clinical pregnancy and ovulation were improved with co‐therapy. These results are similar to those found in a systematic review (<a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a>), where improvements in clinical pregnancy and ovulation were seen with combination therapy however, this did not reflect in live birth rate. <a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a> reported clinical pregnancy rate as their primary outcome therefore only a small number of studies reported the outcome live birth rate, which hinders the statistical power and explains the lack of significance. Given the increased side‐effect profile with metformin, as found in our review (<a href="./references#CD013505-bbs2-0163" title="MorleyLC , TangT , YasminE , NormanRJ , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD003053.pub6] ">Morley 2017</a>), <a href="./references#CD013505-bbs2-0095" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> do not recommend adding in metformin to CC therapy. However, their results are not stratified by BMI. The recent international guidelines that quoted our most recent Cochrane Review as well as one RCT did stratify by BMI and similarly found no difference in live birth rate. We excluded this additional RCT from our recent update because it used hCG injection to trigger ovulation. </p> <p>A recent meta‐analysis in 2018 reported that letrozole should be used first line for ovulation induction given that "the likelihood of live birth is increased 40‐60% with letrozole compared with CC", with reduced rates of failure to ovulate, multiple pregnancy rate and reduced side effects such as hot flushes (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). Concerns arise that letrozole is associated with an increase in potential teratogenic effects however, these findings are yet to be confirmed, with multiple case reviews and a systematic review and meta‐analysis failing to determine any significant association (<a href="./references#CD013505-bbs2-0113" title="DiamondMP . Letrozole, gonadotropin, or clomiphene for unexplained infertility. New England Journal of Medicine2015;373(13):1230‐40. ">Diamond 2015</a>; <a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a>). It was beyond the scope of this Cochrane update to directly compare letrozole with CC however, we were unable to find any studies that directly compared metformin with letrozole. Letrozole is considered first line in some countries because it has been shown to improve ovulation, pregnancy, live birth and reduce the multiple pregnancy rate (<a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a>). </p> <p>The 2018 meta‐analysis compared LOD to metformin directly using two of the three studies included in this review (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). They concluded, in accordance with our findings, that there were insufficient data on whether LOD improves live birth rate, clinical pregnancy or ovulation rates. As a result, they recommend LOD as second‐line treatment in women who are CC‐resistant or first‐line if laparoscopy is indicated for an alternative reason (<a href="./references#CD013505-bbs2-0137" title="NHRMC . International evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Monash University, Melbourne Australia2018;1(https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline):1‐199. ">NHMRC 2018</a>). Similarly <a href="./references#CD013505-bbs2-0159" title="WangR , KimBV , VanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j:138. ">Wang 2017</a> found insufficient evidence of benefit with metformin compared with LOD. They emphasise that women should be counselled carefully about the risks of surgery, including periadnexal adhesion formation, risk of reduced ovarian reserve or loss of ovarian function and increased intra‐operative and post‐operative risks especially in obese women. </p> </section> <section id="CD013505-sec-0183"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>This update focused on women with subfertility with a desire to conceive, therefore we excluded studies if reproductive outcomes were not the aim of treatment. Nonetheless, an improvement in some metabolic and anthropometric outcomes may improve the success of reproductive outcomes and subsequent health. </p> <p>Our review found mixed evidence of an effect of metformin on metabolic outcomes, which is of unclear clinical significance for the prevention of diabetes in the long term. These findings are supported by a Diabetes Prevention Program Research group study of over 3000 obese women (mean BMI 34 kg/m<sup>2</sup>) with an average follow‐up period of 2.8 years (<a href="./references#CD013505-bbs2-0128" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346:393‐403. ">Knowler 2002</a>). They reported that both metformin and lifestyle‐intervention groups (7.8 and 4.8 cases per 100 person years respectively) had a lower incidence of diabetes compared with placebo (11 per 100 person years). However, the lifestyle‐intervention group achieved a significantly better weight reduction compared with the metformin group (58% versus 31%). Furthermore, the initial modest weight loss in the metformin group was not sustainable after three years of follow‐up. In contrast, in the lifestyle group, an average of 4% weight loss was still maintained after four years. Likewise, the Finnish Diabetes Prevention Study demonstrated that weight loss improved insulin sensitivity, waist circumference and serum triglyceride levels compared with controls in 150 obese women with impaired glucose tolerance (<a href="./references#CD013505-bbs2-0156" title="UusitupaM , LouherantaA , LindstromJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83 Suppl 1:137‐42. ">Uusitupa 2000</a>). A 2007 meta‐analysis also concluded that lifestyle interventions are more effective than metformin in reducing the rate of progression to type 2 diabetes in obese women with impaired glucose tolerance (<a href="./references#CD013505-bbs2-0121" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. ">Gillies 2007</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013505-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram 2019 update" data-id="CD013505-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram 2019 update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD013505-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013505-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1. Metformin versus placebo or no treatment, outcome 1.1, live birth rate" data-id="CD013505-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1. Metformin versus placebo or no treatment, outcome 1.1, live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2. Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1, live birth rate" data-id="CD013505-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 2. Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1, live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 3. Metformin versus clomiphene citrate, outcome 3.1, live birth rate" data-id="CD013505-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 3. Metformin versus clomiphene citrate, outcome 3.1, live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Metformin and clomiphene citrate versus clomiphene citrate alone, outcome: 2.4 Ovulation rate." data-id="CD013505-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Metformin and clomiphene citrate versus clomiphene citrate alone, outcome: 2.4 Ovulation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 1 Live birth rate." data-id="CD013505-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 1 Live birth rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 2 Adverse events (gastrointestinal side effects)." data-id="CD013505-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 2 Adverse events (gastrointestinal side effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 3 Clinical pregnancy rate." data-id="CD013505-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 4 Ovulation rate." data-id="CD013505-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 4 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 5 Miscarriage rate per woman." data-id="CD013505-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 5 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 6 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 6 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 7 Multiple pregnancy rate." data-id="CD013505-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 7 Multiple pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 8 Sensitivity analysis: multiple pregnancy rate per pregnancy." data-id="CD013505-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 8 Sensitivity analysis: multiple pregnancy rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 9 Body mass index (kg/m2)." data-id="CD013505-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 9 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 10 Serum testosterone (nmol/L)." data-id="CD013505-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 10 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 11 Serum sex hormone‐binding globulin (nmol/L)." data-id="CD013505-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 11 Serum sex hormone‐binding globulin (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 12 Fasting glucose (mmol/L)." data-id="CD013505-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 12 Fasting glucose (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 13 Fasting insulin (mIU/L)." data-id="CD013505-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 13 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 1 Live birth rate." data-id="CD013505-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 2 Adverse events (gastrointestinal side effects)." data-id="CD013505-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 2 Adverse events (gastrointestinal side effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 3 Clinical pregnancy rate." data-id="CD013505-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 4 Ovulation rate." data-id="CD013505-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 4 Ovulation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate." data-id="CD013505-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 6 Miscarriage rate per woman." data-id="CD013505-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 6 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 8 Multiple pregnancy rate per woman." data-id="CD013505-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 8 Multiple pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 9 Senstivity analysis: multiple pregnancy rate per pregnancy." data-id="CD013505-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 9 Senstivity analysis: multiple pregnancy rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 10 Body mass index (kg/m2)." data-id="CD013505-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 10 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 11 Serum testosterone (nmol/L)." data-id="CD013505-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 11 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 12 Fasting glucose (mmol/L)." data-id="CD013505-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 12 Fasting glucose (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 13 Fasting insulin (mIU/L)." data-id="CD013505-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Metformin and clomiphene citrate versus clomiphene citrate alone, Outcome 13 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 1 Live birth rate." data-id="CD013505-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 1 Live birth rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 2 Clinical pregnancy rate." data-id="CD013505-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 2 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 3 Ovulation rate." data-id="CD013505-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 3 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 4 Miscarriage rate per woman." data-id="CD013505-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 4 Miscarriage rate per woman.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 6 Multiple pregnancy rate per woman." data-id="CD013505-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 6 Multiple pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 7 Sensitivity analysis: multiple pregnancy rate per pregnancy." data-id="CD013505-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 7 Sensitivity analysis: multiple pregnancy rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 8 Body mass index (kg/m2)." data-id="CD013505-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 8 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 9 Serum testosterone (nmol/L)." data-id="CD013505-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 9 Serum testosterone (nmol/L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 10 Fasting glucose (mmol/L)." data-id="CD013505-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 10 Fasting glucose (mmol/L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 11 Fasting insulin (mIU/L)." data-id="CD013505-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 11 Fasting insulin (mIU/L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 1 Live birth rate." data-id="CD013505-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 2 Adverse events (gastrointestinal side effects)." data-id="CD013505-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 2 Adverse events (gastrointestinal side effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 3 Clinical pregnancy rate." data-id="CD013505-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 4 Miscarriage rate per woman." data-id="CD013505-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 4 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Metformin and letrozole versus letrozole alone, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 1 Live birth rate." data-id="CD013505-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 2 Clinical pregnancy rate." data-id="CD013505-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 3 Miscarriage rate per woman." data-id="CD013505-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 3 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 4 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone, Outcome 4 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 1 Live birth rate." data-id="CD013505-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 2 Adverse events (gastrointestinal side effects)." data-id="CD013505-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 2 Adverse events (gastrointestinal side effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 3 Clinical pregnancy rate." data-id="CD013505-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 4 Ovulation rate." data-id="CD013505-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 4 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 5 Miscarriage rate per woman." data-id="CD013505-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 5 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 6 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD013505-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 6 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 7 Body mass index (kg/m2)." data-id="CD013505-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 7 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013505-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/urn:x-wiley:14651858:media:CD013505:CD013505-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_t/tCD013505-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 8 Serum testosterone (nmol/L)." data-id="CD013505-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Metformin versus laparoscopic ovarian drilling, Outcome 8 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013505/media/CDSR/CD013505/image_n/nCD013505-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013505-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : women with polycystic ovary syndrome<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000<br/> (188 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> (1.00 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>302 per 1000 (221 to 397)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.00</b> </p> <p>(2.63 to 6.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I<sup>2</sup> = 39% due to 1 study <a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>153 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000 (210 to 323)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.98</b> </p> <p>(1.47 to 2.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1213<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>242 per</p> <p>1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000 (371 to 545)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.64</b> </p> <p>(1.85 to 3.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>684<br/> (13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I<sup>2</sup> = 61% (82% in non‐obese group) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> <p>(20 to 89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b><br/> (0.50 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy: OR 0.58, 95% CI 0.25 to 1.34; 200 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to report methods of randomisation and/or serious risk of attrition bias in some of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as the event rate is low and findings are compatible with benefit in one or both groups or with no meaningful difference between the groups.<br/> <sup>c</sup>Moderate inconsistency (I<sup>2</sup> = 39%), but not downgraded, as all heterogeneity is attributable to a single small study and the direction of effect largely consistent.<br/> <sup>d</sup>Downgraded one level for serious inconsistency (I<sup>2</sup> = 62%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared with placebo or no treatment for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013505-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting</b> : outpatient<br/> <b>Intervention</b> : metformin combined with ovulation induction agent clomiphene citrate<br/> <b>Comparison</b>: Clomiphene citrate alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CC alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin combined with CC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>281 per 1000</p> <p>(232 to 337)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.27</b> </p> <p>(0.98 to 1.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1219<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> <p>(208 to 372)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.26</b><br/> (2.83 to 6.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>852<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>277 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>383 per 1000</p> <p>(336 to 432)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.62</b><br/> (1.32 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1790<br/> (19 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>507 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>629 per 1000</p> <p>(581 to 676)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.65</b> </p> <p>(1.35 to 2.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1601<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>101 per 1000</p> <p>(70 to 142)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.35</b><br/> (0.91 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy: OR 1.07 95% CI 0.69 to 1.66; 471 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CC:</b> clomiphene citrate; <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to describe study methods and/or serious risk of attrition bias in several of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as findings are compatible with benefit in one or both groups or with no meaningful difference between the group.<br/> <sup>c</sup>Some evidence of imprecision seen in obese group however only one study included therefore not downgraded, given clear effect seen in BMI &lt; 30 kg/m<sup>2</sup> group.<br/> <sup>d</sup>High heterogeneity (I<sup>2</sup> = 63%), but not downgraded as direction of effect consistent and most inconsistency is due to a single small study.<br/> <sup>e</sup>Downgraded one level for evidence of publication bias seen with three studies outside the funnel plot and asymmetry around the line of effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013505-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting:</b> outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: clomiphene citrate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> <p><sup>a</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> <p>(256 to 503)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> (1.00 to 2.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High heterogeneity (I<sup>2</sup> = 78%) </p> <p>76 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> <p>(45 to 125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b> </p> <p>(0.17 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>(gastrointestinal)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b><sup>a</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>352 per 1000 (270 to 444)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b><br/> (1.06 to 2.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000 (74 to 173)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.34</b><br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p><sup>f</sup>Participants with BMI &lt; 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>650 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>597 per 1000 (491 to 699)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.80</b><br/> (0.52 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p><sup>f</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>516 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1,000<br/> (176 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b><br/> (0.20 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> <p><sup>a</sup>Participants with BMI &lt; 30 kg/<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000 (36 to 182)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.51</b> (0.62 to 3.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 events</p> <p>Miscarriage rate per pregnancy: OR 1.02 (0.41 to 2.54)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> <p><sup>a</sup>Participants with BMI ≥ 30 kg/m<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000 (18 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.61</b> (0.27 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 events; only 1 study with events</p> <p>Miscarriage rate per pregnancy: OR 1.92 (0.72 to 5.12)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> &gt; 85%) with differing directions of effect.<br/> <sup>b</sup>Evidence downgraded one level for risk of bias.<br/> <sup>c</sup>Evidence downgraded one level for serious imprecision: low event rate and/or wide confidence intervals.<br/> <sup>d</sup>Evidence downgraded for high heterogeneity.<br/> <sup>e</sup>Evidence downgraded for serious imprecision; many small studies with wide confidence intervals.<br/> <sup>f</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> = 74%), though direction of effect was consistent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared with clomiphene citrate for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body mass index</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computerised tomography scan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follicle‐stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose tolerance test</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycosylated haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LOD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Laparoscopic ovarian drilling</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIDDM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non insulin dependent diabetes mellitus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised controlled trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant follicle‐stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error of the mean</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Versus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert from</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert to</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conversion factor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin versus placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0001" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0040" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. ">Yarali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0007" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0010" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0022" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 1.00</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0030" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin versus placebo: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin and clomiphene citrate versus clomiphene citrate alone: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin +<br/> clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0003" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0004" title="BoudhraaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study about 63 cases. La Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0023" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0024" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0026" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , Van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0029" title="NgEH , WatNM , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0011" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0015" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL , KhorramO , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0028" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0009" title="HeathcoteG , ForbesK , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind placebo‐controlled trial. Unpublished data. ">Heathcote 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0036" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0037" title="SturrockND , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0039" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin and clomiphene citrate versus clomiphene citrate alone: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin versus clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0032" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0033" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand) a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with polycystic ovary syndrome evaluating metformin for infertility with clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0019" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0041" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.32</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin versus clomiphene citrate: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metformin and letrozole vs letrozole: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin and letrozole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Letrozole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0021" title="LiuC , FengG , HuangW , WangQ , YangS , TanJ , et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecological Endocrinology2017;33(11):872‐6. ">Liu 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.49</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metformin and letrozole vs letrozole: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Metformin and laparoscopic ovarian drilling (LOD) vs LOD: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin &amp; LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0018" title="KocakI , UstinC . Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. Japan Society of Obstetrics and GynecologyJanuary 2006;32(3):292‐8. ">Kocak 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Metformin and laparoscopic ovarian drilling (LOD) vs LOD: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013505-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Metformin vs laparoscopic ovarian drilling (LOD): ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>LOD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0031" title="PalombaS , OrioF , NardoLG , FalboA , RussoT , CoreaD , et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate‐resistant women with polycystic ovary syndrome: a prospective parallel randomized double‐blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2004;89(10):4801‐9. ">Palomba 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013505-bbs2-0008" title="HamedHO , HasanAF , AhmedOG , AhmendMA . Metformin versus laparoscopic ovarian drilling in clomiphene‐ and insulin‐resistant women with polycystic ovary syndrome. International Journal of Gynecology and Obstetrics2010;108:143‐7. ">Hamed 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.01</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Metformin vs laparoscopic ovarian drilling (LOD): ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/full#CD013505-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.00, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.94, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.51, 16.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (gastrointestinal side effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [2.63, 6.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.68 [3.34, 9.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.92, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.47, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.42, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.98, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.85, 3.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [2.32, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.28, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.50, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.52, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.04, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.25, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.26, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.02, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Sensitivity analysis: multiple pregnancy rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 6.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.29, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.30, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.82, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.48, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.50, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.45, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum sex hormone‐binding globulin (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐4.77, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐6.62, 8.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.23 [‐5.56, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.03, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.28, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.84 [‐4.27, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.77 [‐6.04, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.88 [‐4.84, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin and clomiphene citrate versus clomiphene citrate alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.98, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 or ≤ 32 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.84, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.95, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (gastrointestinal side effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [2.83, 6.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.13 [2.71, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.19, 29.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Participants with BMI not recorded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.75 [0.81, 269.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.32, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.06, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.24, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Participants with BMI not recorded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.39, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.35, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.03, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.26, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 BMI not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [1.65, 8.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [2.46, 9.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PCOS and clomiphene‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [0.65, 19.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PCOS and clomiphene‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.97 [2.46, 10.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.91, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.74, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.81, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.69, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.61, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.54, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Multiple pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.18, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.12, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Senstivity analysis: multiple pregnancy rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.15, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.10, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.08, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.44 [‐6.11, ‐2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Participants with BMI &lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐6.20, ‐1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.04 [‐7.47, ‐2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.60, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.61, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Participants with BMI &lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.47, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.29, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Participants with BMI &lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.64, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.29, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.57 [‐7.84, ‐5.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Participants with BMI &lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.20 [‐18.33, ‐12.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.86 [‐6.26, ‐3.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin and clomiphene citrate versus clomiphene citrate alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin versus clomiphene citrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.49, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.00, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.06, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.21, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.34, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.52, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.20, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.51, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.62, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.27, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.69, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with BMI &lt; 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.41, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with BMI ≥ 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.72, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Multiple pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.07, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis: multiple pregnancy rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.05, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐9.40, ‐0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.82, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.79, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.0 [‐16.96, ‐9.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin versus clomiphene citrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin and letrozole versus letrozole alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.48, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (gastrointestinal side effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.74 [0.94, 299.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.64, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.61, 4.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.51, 4.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metformin and letrozole versus letrozole alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.51, 8.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.79, 12.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.51 [0.25, 122.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 77.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metformin and laparoscopic ovarian drilling versus laparoscopic ovarian drilling alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013505-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Metformin versus laparoscopic ovarian drilling</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.09, 4.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (gastrointestinal side effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.77 [2.43, 24.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.27, 17.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.62 [1.46, 449.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.54, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.83, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.17, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.23, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with BMI &lt; 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.21, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with BMI ≥ 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.08, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.20, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.14, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.14, 6.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐13.48, 6.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐1.09, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Metformin versus laparoscopic ovarian drilling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013505/references#CD013505-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013505&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013505-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013505-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD013505-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013505-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013505-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD013505-note-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013505-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013505"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013505"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013505"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013505\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013505\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013505"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013505&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013505';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013505/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013505/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013505%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719015982"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013505/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719015986"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013505/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dde709c2c1be5',t:'MTc0MDcxOTAxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 